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General Considerations  
 
 
(A) General Analytical Information 
 
  Nuclear Magnetic Resonance spectra were recorded on a Bruker Avance 400 MHz instruments at 
ambient temperature. All 1H NMR spectra were measured in part per million (ppm) relative to the 
signals for tetramethylsilane (TMS) added into the deuterated chloroform (CDCl3) (0 ppm) unless 
otherwise stated. Data for 1H NMR were reported as follows: chemical shift, multiplicity (s = singlet, d 
= doublet, t = triplet, q = quartet, qu = quintet, m = multiplet, ovrlp = overlap; br = broad), coupling 
constants, and integration. All 13C NMR spectra were reported in ppm relative to CDCl3 (77.16 ppm) 
unless otherwise stated, and were obtained with complete 1H decoupling. All GC analyses were 
performed on a Perkin-Elmer Clarus 400 GC system with a FID detector. All GC-MS analyses were 
performed on an Agilent Technologies 7890A GC system equipped with a 5975C MS detector. High-
resolution mass spectra (HRMS) by electrospray ionization (ESI) method were performed at the EPFL 
ISIC Mass Spectroscopy Service with a Micro Mass QTOF Ultima spectrometer.  
 
 
(B) General Reagent Information 
 
  Unless otherwise noted, all chemicals used in the reactions were commercially available and were used 
as received without further purifications. Tetrahydrofuran (THF) was purified and dehydrated using a 
two-column solid-state purification system (Innovative Technology, NJ, U.S.A.) and transferred to the 
nitrogen-filled glove box and further dried with activated 3Å molecular sieves (beads) for storage. 
Anhydrous dimethylacetamide (DMA) (99.8% purity) were purchased from Acros Chemicals in Sure-
Seal bottles and stored under nitrogen. Iron(II) bromide (FeBr2, 98% purity) was purchased from 
Aldrich Chemical Co.. Copper(I) iodide (98% purity) was purchased from Strem Chemicals. Bis(1,5-
cyclooctadiene)nickel(0) (98% purity) was purchased from abcr GmbH. Anhydrous cobalt(II) bromide 
(99% purity) was purchased from Aldrich Chemical Co.. All alkyl halides (starting materials) and the 
resulting alkene products were in form of racemic mixtures unless otherwise noted.  
 
  The following known starting materials (alkyl halides, bromoalkynes, aryl halides and triflates, and 
alkenyl halides) were prepared according to the literature procedures;1-32  
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(i) Alkyl Halides
I I
3-iodononane2 5-iodononane4
I
iodocycloheptane1
I
(3-iodobutyl)benzene4
O I
4-iodotetrahydro-
2H-pyran3
O
Me
O
I
5-iodopentyl acetate11
I
2-iodononane4
I
iodocyclooctane2 I2-iodobicyclo[2.2.1]heptane
(d.r.: exo:endo = 4.3:1)4
I
1-iodoadamantane10
I
10-iododec-1-ene12
CN
I
7-iodoheptanenitrile14
I
2-iodooctane5
I
6-iodo-2-methylhept-2-ene6
I
MeO
1-(2-iodopropyl)-4-methoxybenzene4
I
MeO
4-(2-iodopropyl)-1,2-dimethoxybenzene4
MeO
I
(2-iodopropyl)benzene7
I
2-iodo-2,3-dihydro-1H-indene8
I
(5-iodopentyl)benzene13
O
I
O
2-(allyloxy)-3-
iodotetrahydrofuran9
O
2-(allyloxy)-
3-iodotetrahydro-2H-pyran9
O
I
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Br
O
O
Me
I
O
OMe
(E)-4-(2-bromovinyl)phenyl acetate30 methyl (Z)-3-iodoacrylate31
Br
(E)-1-(2-bromovinyl)-
4-chlorobenzene29
Cl
Br
(E)-5-(2-bromovinyl)-
benzo[d][1,3]dioxole28
Br
(E)-1-(2-bromovinyl)-
4-fluorobenzene28
F
O
O
Br
(E)-5-(2-bromovinyl)-1,2,3-
trimethoxybenzene27
OMe
OMe
OMe
TfO
O
4-benzoylphenyl trifluoromethanesulfonate32
(iii) Aryl and Alkenyl Halides
Br
Br
(bromoethynyl)benzene15
Br
1-(bromoethynyl)-
4-fluorobenzene16
F
Br
1-(bromoethynyl)-
4-nitrobenzene19
NO2
OMeBr
1-(bromoethynyl)-
4-methoxybenzene15
CNBr
4-(bromoethynyl)-
benzonitrile19
Br
1-(4-(bromoethynyl)phenyl)-
ethan-1-one17
O
Me
Br
methyl 4-(bromoethynyl)-
benzoate18
O
OMe
BrBr
1-bromo-4-(bromoethynyl)-
benzene15
Br
1-(bromoethynyl)-
2-methylbenzene20
Me
Br
methyl 3-bromopropiolate15
O
OMe
Br
3-bromo-1-morpholino-
prop-2-yn-1-one22
O
N
O
Br
3-bromo-1-phenylprop-
2-yn-1-one15
O
t-BuBr
1-(bromoethynyl)-
4-(tert-butyl)benzene16
2-(bromoethynyl)-
naphthalene21
ClBr
1-bromo-4-(bromoethynyl)-
benzene16
SiEt3Br
(bromoethynyl)triethylsilane23
Br
O
O
2-((4-bromobut-3-yn-1-yl)oxy)-
tetrahydro-2H-pyran24
O
Br
O
3-bromoprop-2-yn-1-yl
benzoate25
Br
N
O
O
2-(3-bromoprop-2-yn-1-yl)-
isoindoline-1,3-dione26
(ii) Bromoalkynes
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(C) General Manipulation Considerations    
   
  All manipulations for the (i) Fe-catalyzed reductive coupling reactions of alkyl iodides with terminal 
alkynes to alkenylzinc reagents, and (ii) the subsequent transition metal-catalyzed cross-couplings of 
alkenylzinc reagents, were set up in a 30 mL Teflon-screw cap test tube under an inert nitrogen 
atmosphere using the glove-box techniques. The test tubes were then sealed with airtight electrical 
tapes and the reaction mixtures were stirred under nitrogen atmosphere at room temperature on bench-
top or heated in a preheated oil bath. Flash column chromatography was performed using silica gel 
(Silicycle, ultrapure grade). Preparative thin layer chromatography (preparative TLC) was used to 
purify the trisubstituted alkene products using TLC silica gel 60 F254 glass plate (Merck). The eluents 
for column chromatography and preparative TLC are presented as a ratio of solvent volumes.  
 
  The yields reported in the publication are of isolated materials unless otherwise noted. All new 
trisubstituted alkene products were characterized by 1H NMR and 13C NMR spectroscopies and high-
resolution mass spectrometry (HRMS); in case the molecular ions could not be detected by HRMS, 
GC-MS was used instead.  
 
  The major stereoisomers of trisubstituted alkene products (Figures 1 and 3 in the main text; Figure S1 
and S3 in Supporting Information) and the corresponding minor stereoisomers were differentiated by 
comparing the chemical shifts of the olefinic protons of product isomers with the stereochemically 
similar, known compounds.33,34 The stereospecific trisubstituted alkenes products (Figure 2 in the main 
text; Figure S2 in Supporting Information) were supported by comparing the 1H NMR spectrum of 
product S3a (Table S2) with the authentic compound.35 The ratio of the stereoisomers of trisubstituted 
alkene product was determined by comparing the ratio of the integrations of olefinic protons by 1H 
NMR spectroscopy.  
 
  In case diastereomers exist in 1:1 ratio in the α-alkylated styene products (Figures 3 and S3), the 
multiplicity of the splitting of proton signals in the 1H NMR spectra were not shown due to the 
complexity of the proton signals. Moreover, the chemical shifts of carbon signals in the 13C NMR 
spectra were represented as “number (number)” for the same carbons of the diastereomers.  
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Supplementary Experimental Results 
 
(A) Optimization of Cu-Catalyzed Cross-Coupling of Alkenylzinc Reagents with Bomoalkynes  
   
  The Z-disubstituted alkenylzinc reagent was prepared by using a procedure similar to that used in our 
previous study36 (by using ethynylbenzene (0.14 mmol, 1 equiv) and excess iodocyclohexane (1.5 equiv) 
as reagents, FeBr2 (10 mol %) as catalyst, Zn as redundant (1.5 equiv), iodine (~2 mol %) as zinc 
activating reagent, and DMA (~0.3 mL) as solvent). The in-situ formed alkenylzinc reagent was then 
diluted with THF (volume ratio THF to DMA ~ 6:1). In the reaction of excess alkenylzinc reagent (up to 
1.4 equiv assuming 100% conversion in the first step) with (2-bromoethynyl)benzene (test substrate, 1 
equiv, 0.10 mmol), the use of CuCl catalyst (20 mol %) in conjunction with 2,2-dibypridyl (20 mol %) 
could catalyze the reaction to give the E-enyne product in 49% GC yield (Table S1, entry 1). Other 
bidentate nitrogen and phosphine ligands did not promote the reaction as efficiently as bipy (Table S1, 
entries 2-6). By using iodotrimethylsilane as Zn activating reagent, the yield of enyne was significantly 
enhanced to 87% yield (Table S1, entry 7). The product yield can be further slightly increased to 91% 
when a lower loading of CuCl (15 mol %) was used (Table S1, entry 8). By switching the catalyst to 
CuI, the highest yield (95%) was obtained (Table S1, entry 9). However, the lowering of the loading of 
bipy or CuI led to the decrease of yields (Table S1, entries 10 and 11). Other Cu catalysts were also 
screened but they did not catalyze the reactions as efficiently as CuI (Table S1, entries 12-18). The use 
of other Zn activating reagents, bromo- and chlorotrimethylsilane (TMSBr and TMSCl), did not lead to 
a higher yielder yield compared to TMSI (Table S1, entries 19 and 20). Without CuI, the reaction was 
sluggish and only a modest yield was obtained (Table S1, entry 21). The conditions in entry 9 were used 
as the optimal general conditions for substrate scope study.  
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Table S1. Complete Optimization of Cu-Catalyzed Cross-Coupling of Alkenylzinc Reagents with 
Bomoalkynes  
   
   
 
 
 
 
Ph
(max. 1.4 equiv 
w.r.t. bromoalkyne)
Br
(1 equiv)
CuX (mol %)Cy
Ph
PhPh
+
Cy
(1 equiv)
(1.5 equiv)
FeBr2 (10 mol %)
Zn (1.5 equiv)
Cy
ZnI
ligand (mol %)
THF, rt, 10 h
additive
DMA, rt, 16 h
entry additive (mol %) CuX (mol %) ligand (mol %) GC yield (%)a
I2 (2) CuCl (20) bipy (20) 491
I2 (2) CuCl (20) phenanthroline (20) 463
TMSI (10) CuCl (20) bipy (20) 877
TMSI (10) CuCl (15) bipy (20) 918
TMSI (10) CuI (15) bipy (20) 959
TMSI (10) CuI (15) bipy (15) 7910
TMSI (10) CuI (10) bipy (20) 8311
TMSI (10) CuI (0) bipy (20) 4121
Ph
I
(a) GC yield using n-dodecane as internal standard.
I2 (2) CuCl (20) (20) 272
N N
t-Bu t-Bu
I2 (2) CuCl (20) TMEDA (80) 484
I2 (2) CuCl (20)  (20) 285
I2 (2) 246
Ph2P PPh2
Cy2P PCy2 (20)
TMSI (10) CuBr (15) bipy (20) 8312
TMSI (10) Cu(MeCN)4PF6 (15) bipy (20) 9413
TMSI (10) 1/2 [Cu(OTf)]2  benzene (15) bipy (20) 7814
TMSI (10) bipy (20) 8715
TMSI (10) CuCN (15) bipy (20) 8916
TMSI (10) CuOAc (15) bipy (20) 9017
TMSI (10) CuTc (15) bipy (20) 8418
CuSCN (15)
TMSBr (10) CuI (15) bipy (20) 8919
TMSCl (10) CuI (15) bipy (20) 8120
CuCl (20)
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(B) Optimization of Ni-Catalyzed Cross-Coupling of Alkenylzinc Reagents with Aryl Halides 
 
  The in-situ formed alkenylzinc reagent solution was prepared using conditions optimized in Table S1.36 
In the reaction of excess alkenylzinc reagents (up to 1.25 equiv assuming 100% conversion in the first 
step) with ethyl 4-bromobenzoate (test substrate, 1 equiv, 0.10 mmol), the effect of ligand was first 
studied in the presence of Ni(cod)2 catalyst (20 mol %). The use of phosphine-type ligands only led to 
the formation of the α-phenylstyrene product in low yields (Table S2, entries 1-8). On the contrary, the 
use of bidentate nitrogen-type ligands could generally give higher yields (Table S2, entries 9-13), and 
2,2’-dipyridiyl ligand was found to be the optimal ligand to give the product in 64% yield (Table S2, 
entry 9). Further screening demonstrated that the yield was highest (76%) when Ni(cod)2 (10 mol %) 
and bipy (15 mol %) were used (Table S2, entry 14). Without a Ni catalyst, only a low yield of was 
obtained (Table S2, entry 16). Nickel(II) precatalysts, NiII(TMEDA)(o-tolyl)(Cl)37 and NiIIBr2(diglyme), 
did not efficiently catalyze the reaction as compared to Ni(cod)2 despite the use of other derivatives of 
2,2’-dipyridiyl ligands (Table S2, entries 17-21). The conditions in entry 14 were used as the optimal 
general conditions for substrate scope study of aryl halides and other sp2-carbon halogen bonds.  
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Table S2. Complete Optimization of Ni-Catalyzed Cross-Coupling of Alkenylzinc Reagents with 
ArBr  
 
Ph
(max. x equiv 
w.r.t. ArBr)
(1 equiv)
Ni catalyst (mol %)Cy
Ph
FeBr2 (10 mol %)
Zn (1.5 equiv)
Cy
ZnI
ligand (mol %)
THF, 70 oC, 10 h
TMSI (10 mol %)
DMA, rt, 16 h
entry Ni catalyst (mol %) ligand (mol %) GC yield (%)a
Ph
+
Cy
(1 equiv)
(1.5 equiv)
I
alkenyl-ZnI (x equiv)
1.25 Ni(cod)2 (20) dppe (20) 91
1.25 Ni(cod)2 (20) bipy (20) 649
1.4 Ni(cod)2 (10) bipy (15) 7614
1.4 Ni(cod)2 (15) bipy (15) 6215
CO2Et
1.4 Ni(cod)2 (0) bipy (15) 1816
Br CO2Et
1.25 Ni(cod)2 (20) dppp (20) 82
1.25 Ni(cod)2 (20) dppb (20) 163
1.25 Ni(cod)2 (20) dppf (20) 164
1.25 Ni(cod)2 (20) PPh3 (80) 225
1.25 Ni(cod)2 (20) BINAP (20) 86
1.25 Ni(cod)2 (20) Xantphos (20) 117
1.25 Ni(cod)2 (20) 3610
N N
t-Bu t-Bu
1.25 Ni(cod)2 (20) 1811 phen (20)
1.25 Ni(cod)2 (20) 5912
N N
Me Me
(20)
(20)
1.25 Ni(cod)2 (20) 2813 (20)N
OO
N
1.25 Ni(cod)2 (20) (20) 158
Ph2P PPh2
(a) GC yield using n-dodecane as an internal standard.
1.25 Ni(cod)2 (10) bipy (10) 4220
1.25 NiBr2(diglyme) (10) bipy (10) 2721
Me1N NMe2
Ni
Cl
Me
(10) bipy (15) 681.417
Me1N NMe2
Ni
Cl
Me
(10) 621.418
N N
t-Bu t-Bu
(15)
Me1N NMe2
Ni
Cl
Me
(10) 491.419
N N
MeO OMe
(15)
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(C) Optimization of Co-Catalyzed Cross-Coupling of Alkenylzinc Reagents with Alkyl Iodides 
 
  The in-situ formed alkenylzinc reagent solution was prepared using optimized conditions in Table S1.36  
In the reaction of excess alkenylzinc reagent (up to 1.4 equiv assuming 100% conversion in the first 
step) with 2-iodooctane (test substrate, 1 equiv, 0.10 mmol), the use of CoBr2 (10 mol %) in conjunction 
with TEMDA (2 equiv) were found to catalyze the reaction to give the α-alkylstyrene product in 47% 
yield (Table S3, entry 1). The increase of loading of CoBr2 to 20 mol % further increased the yield to 
57% (Table S3, entry 2), but the further increase of loading of CoBr2 (30 and 40 mol %) could not 
further enhance the yield (Table S3, entries 3 and 4). The use of TMEDA derivatives, N,N,N’,N’-
tetramethyl-1,3-propanediamine (TMPDA) and N,N,N’,N’-tetraethylethylenediamine (TEEDA), only 
led to modest yields (Table S3, entries 5 and 6). The incorporation of flame-dried LiCl into either 
alkenylzinc reagent or various cobalt halide catalysts could not promote the yields (Table S3, entries 7-
9). The additional use of 3 equiv of pyridine co-ligand was found to further enhance the yield to 67% 
yield (Table S3, entry 10). By using a higher loading of alkenylzinc reagent (1.7 equiv), the use of 
CoBr2/TMEDA/pyridine catalyst system could led to a highest yield of product in 76% yield (Table S3, 
entry 12). The subsequent tuning of loading of either TMEDA or pyridine did not promote the yield 
further (Table S3, entries 13-15). Additionally, the conditions in entry 12 also allowed for the coupling 
of primary alkyl iodide, 1-iodooctane (test substrate, 0.10 mmol), to give the desired product in 76% 
yield Table S3, entry 12). Without CoBr2 catalyst, only trace amounts of products were obtained (Table 
S3, entry 16). The conditions in entry 12 were used as the optimal general conditions for study of 
substrate scope of alkyl halides. 
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Table S3. Complete Optimization of Co-Catalyzed Cross-Coupling of Alkenylzinc Reagents with 
Alkyl Iodides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7 CoBr2 (20) TMEDA (1.5), pyridine (2) 7015
1.7 CoBr2 (20) TMEDA (1.5), pyridine (4) 7014
Ph
(max. x equiv 
w.r.t. 2-iodooctane)
(1 equiv)
Co catalyst (mol %)Cy
Ph 2-octylFeBr2 (10 mol %)
Zn (1.5 equiv)
Cy
ZnI
ligand (equiv)
THF, rt, 10 h
TMSI (10 mol %)
DMA, rt, 16 h
entry Co catalyst (mol %) ligand(s) (equiv) GC yield (%)a
2-iodooctanePh
+
Cy
(1 equiv)
(1.5 equiv)
I
alkenyl-ZnI (x equiv)
1.4 CoBr2 (10) TMEDA (2) 471
1.7 CoBr2 (20) TMEDA (2), py (3) 76 (76)b12
1.4 CoBr2 (20) TMEDA (2), py (3) 6710
1.4 CoBr2 (20) TMEDA (2) 572
1.4 (+ 1.4 equiv LiCl) CoBr2 (20) TMEDA (2) 497
1.4 CoBr2   2LiCl(30) TMEDA (2) 228
1.7 CoBr2 (0) TMEDA (2), py (3) <5 (<1)b16
1.4 CoBr2 (30) TMEDA (2) 573
1.4 CoBr2 (40) TMEDA (2) 534
1.4 CoBr2 (30) TMPDA (2) 265
1.4 CoBr2 (30) TEEDA (2) 376
1.4 CoCl2   2LiCl(30) TMEDA (2) 59
1.4 CoBr2 (20) TMEDA (1.5), py (3) 4511
(a) GC yield using n-dodecane as an internal standard. (b) 1-Iodooctane was used instead of 
2-iodooctane.
1.7 CoBr2 (20) TMEDA (2), pyridine (4) 6613
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(D) Supplementary Results of Cu-Catalyzed Cross-Coupling of Alkenylzinc Reagents with 
Bromoalkynes 
 
 
 
Figure S1. Cu-catalyzed cross-coupling of alkenylzinc reagents with bromoalkynes.  
 
 
 
 
 
 
 
 
Ar
(up to 1.7 equiv 
w.r.t. bromoalkyne)
Br (1 equiv)
CuI (15 mol %)R
ArR'
Ar
+
R
(1 equiv)
(1.5 equiv)
FeBr2 (10 mol %)
Zn (1.5 equiv)
R
ZnI
bipy (20 mol %)
THF, rt, 16 h
TMSI (10 mol %)
DMA, rt, 16 h
R'
I
MeO
S2f: 49%c
O
Cl
MeO
S2a: 44%
t-Bu
S2c: 46%a
t-Bu
SMe
S2b: 43%a
t-Bu
SMe
MeO
S2e: 41%c
N
O
O
S2d: 39%b
Me
SMe
MeO
S2g: 44%c
O
O
Cl
S2
(a) Alkyl iodide (2 equiv) and Zn (2 equiv) were used in the first step. (b) Alkyl iodide (3 equiv), Zn (3 equiv) and TMSI (20 
mol %) were used in the first step. (c) CuI (25 equiv) and bipy (35 equiv) were used in the second step.
MeS
S2h: 37%
O
O
(E:Z = 17:1) (E:Z > 40:1) (E:Z > 20:1)
(E:Z = 18:1) (E:Z = 17:1) (E:Z = 18:1)
(E:Z = 16:1) (E:Z > 20:1)
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(E) Supplementary Results of of Ni-Catalyzed Cross-Coupling of Alkenylzinc Reagents with sp2-
Carbon-Halogen Bonds 
 
 
 
Figure S2. Ni-catalyzed cross-coupling of alkenylzinc reagents with sp2-carbon-halogen bonds. In all 
products, the ratios of major to minor isomer are more than 50:1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ar
(up to 1.7 equiv 
w.r.t. R'X)
(1 equiv)
Ni(cod)2 (10 mol %)R
ArFeBr2 (10 mol %)
Zn (1.5 equiv)
R
ZnI
bipy (15 mol %)
THF, 70 oC, 16 h
TMSI (10 mol %)
DMA, rt, 16 h
Ar
+
R
(1 equiv)
(1.5 equiv)
I
R'R' X
S3
Me
X = Br
S3a: 42%a
MeO
X = I
S3c: 54%
O
OMe O
OMe
I
From:
Me
X = Br
S3b: 50%b
O
O
Me
(a) Alkyl iodide (3 equiv), Zn (3 equiv), and TMSI (20 mol %) were used in the first step. (b) Alkyl iodide (1.8 equiv) 
and Zn (1.8 equiv) were used in the first step.
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(F) Supplementary Results of of Co-Catalyzed Cross-Coupling of Alkenylzinc Reagents with Alkyl 
Iodides  
 
 
 
Figure S3. Co-catalyzed cross-coupling of alkenylzinc reagents with alkyl iodides.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ar
(up to 1.5 equiv 
w.r.t. alkyl-I)
(1 equiv)
CoBr2 (20 mol %)R
Ar alkylFeBr2 (10 mol %)
Zn (1.8 equiv)
R
ZnI
TMEDA (2 equiv), py (3 equiv)
THF, rt, 16 h
TMSI (10 mol %)
DMA, rt, 16 h
alkyl-IAr
+
R
(1 equiv)
(1.8 equiv)
I
S4
S4b: 44%
FMe
S4c: 37%a,b
OMet-Bu
OMe
S4a: 48%a
MeO
S4d: 38%a
t-Bu
OMe
S4e: 26%
t-Bu
CN
S4f: 33%
t-Bu
(a) Alkenylzinc reagent (1.7 equiv with repsect to alkyl iodide) was used in the second step. (b) Alkyl iodide (1.5 equiv) 
and Zn (1.5 equiv) were used in the first step.
O
O
S
(Z :E  > 20:1) (Z :E  = 16:1) (Z :E  = 6.6:1)
(Z :E  = 40:1) (Z :E  = 7.8:1) (Z :E  = 7.1:1)
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Experimental Section  
 
 
General Procedure for the Preparation of Alkyl Halide from Alkyl Alcohol.4 A 1 L round-bottom 
flask equipped with a Teflon-coated magnetic stir bar was charged with triphenylphosphine (1.4 equiv), 
imidazole (1.4 equiv), and dichloromethane (~300 mL). The reaction mixture was stirred at room 
temperature until most of the white solids dissolved. Iodine (1.4 equiv) was then added slowly in a few 
portions into the reaction mixture, and the resulting mixture was stirred until the iodine granules almost 
dissolved. Alkyl alcohol (1.0 equiv) was then slowly added into the reaction mixture, and the resulting 
mixture was stirred overnight. After the reaction, the reaction mixture was concentrated with the aid of a 
rotary evaporator, and it was further diluted with hexanes and filtered to remove the solid residues. The 
filtrate was concentrated in vacuo with the aid of a rotary evaporator. The residue was purified by flash 
column chromatography with silica gel using hexanes and ethyl acetate as eluent to afford the following 
alkyl iodides. The following compounds were synthesized using the general procedures:  
 
 
 
 
 
 
 
General Procedure for the Preparation of Bromoalkyne.  
 
(i) From Terminal Alkynes.15,16 A 100 mL round-bottom flask equipped with a Teflon-coated magnetic 
stir bar was charged with alkyne (1 equiv) and silver nitrate (10 mol %). Acetone (~30 mL) and water 
(~1 mL) were then added into the flask, followed by the addition of N-bromosuccinimide (NBS) (1.1 
equiv). The resulting mixture was stirred overnight. After the reaction, the reaction mixture was washed 
with NaOH solution (~1 M, 50 mL) and dichloromethane (20 mL). The aqueous layer was further 
washed with dichloromethane (2 x 20 mL). The organic fractions were combined and concentrated in 
vacuo with the aid of a rotary evaporator. The residue was purified by flash column chromatography 
with silica gel using hexanes and ethyl acetate as eluent to afford the following bromoalkynes. The 
following compounds were synthesized using the general procedures: 
 
I
F
1-fluoro-4-(2-iodopropyl)benzene
MeO I
3-iodo-1-methoxybutane
I
Cl
1-chloro-8-iodooctane
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(ii) From Aryl-aldehyde.20 A 1 L round-bottom flask equipped with a Teflon-coated magnetic stir bar 
was charged with triphenylphosphine (3 equiv) and dichloromethane (~300 mL). Tetrabromomethane 
(1.5 equiv) was then added slowly into the reaction mixture, and the reaction mixture was stirred at 
room temperature until most of the solids dissolved. Aryl-aldehyde (1 equiv) was added into the reaction 
mixture, and the resulting mixture was stirred overnight. After the reaction, the reaction mixture was 
concentrated with the aid of a rotary evaporator, and it was further diluted with hexanes and filtered to 
remove the solid residues. The filtrate was concentrated in vacuo with the aid of a rotary evaporator. The 
residue was purified by flash column chromatography with silica gel using hexanes and ethyl acetate as 
eluent to afford the (2,2-dibromovinyl)arene. A 500 mL round-bottom flask equipped with a Teflon-
coated magnetic stir bar was charged with (2,2-dibromovinyl)arene (1 equiv, prepared from the previous 
procedure), benzyltriethylammonium chloride (0.88 equiv), and dichloromethane (~100 mL). A solution 
of KOH (~50 equiv) in water (~30-40 mL) was slowly added into the reaction mixture, and the resulting 
mixture was stirred vigorously at room temperature overnight. The reaction conversion was monitored 
by GC analysis. After the reaction, the reaction mixture was diluted with water (~200 mL). The organic 
fraction was isolated, and the aqueous layer was further washed with dichloromethane (2 x 50 mL). The 
organic fractions were combined and concentrated in vacuo with the aid of a rotary evaporator. The 
residue was purified by flash column chromatography with silica gel using hexanes and ethyl acetate as 
eluent to afford the following bromoalkynes. The following compound was synthesized using the 
general procedures: 
 
 
 
 
 
O
O
Br
(4-((5-bromopent-4-yn-1-yl)oxy)phenyl)-
(phenyl)methanone
OBr
O
Cl5-bromopent-4-yn-1-yl4-chlorobenzoate
OBr
Cl
1-((6-bromohex-5-yn-1-yl)oxy)-
4-chlorobenzene
SMeBr
(4-(bromoethynyl)phenyl)-
(methyl)sulfane
OMe
OMe
OMe
Br
5-(bromoethynyl)-1,2,3-
trimethoxybenzene
N
Et
Br
3-(bromoethynyl)-9-ethyl-9H-carbazole
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General Procedure for the Iron-Catalyzed Reductive Coupling of Terminal Alkyne and Alkyl 
Iodide to Prepare in-situ Formed Z-Substituted Alkenylzinc Reagent (General Procedure A). An 
oven-dried 30 mL re-sealable screw-cap test tube equipped with a Teflon-coated magnetic stir bar was 
charged with zinc powder (Zn, 69 mg, 1.05 mmol, 1.5 equiv), iron(II) bromide (FeBr2, 15 mg, 0.07 
mmol, 10 mol %), and DMA solvent (1.5 mL). Iodotrimethylsilane (TMSI, 14 mg, 0.07 mmol, 10 mol 
%) was then added into the reaction mixture, and the mixture was stirred at room temperature for ~1 min 
(Caution: white fume was generated when iodotrimethylsilane was once added; no more fume was 
produced upon prolonged stirring). Ethynylarene (0.70 mmol, 1.0 equiv) was added into the reaction 
mixture followed by the addition of alkyl iodide (1.05 mmol, 1.5 equiv). The resulting mixture was 
stirred at room temperature for 16 h. After the reaction, THF (9 mL) was added into the resulting 
mixture to form the in-situ formed Z-disubstituted alkenylzinc reagent.  
 
 
General Procedure for the Copper-Catalyzed Cross-Coupling of in-situ Formed Alkenylzinc 
Reagent with Bromoalkyne (General Procedure B). An oven-dried 30 mL re-sealable screw-cap test 
tube equipped with a Teflon-coated magnetic stir bar was charged with bromoalkyne (0.41 mmol, 1.0 
equiv), copper(I) iodide (CuI, 12 mg, 0.062 mmol, 15 mol %), and 2,2’-dipyridyl (bipy, 13 mg, 0.082 
mmol, 20 mol %). The solution of in-situ formed Z-disubstituted alkenylzinc reagent in THF/DMA 
(prepared in General Procedure A; ~0.7 mmol (assuming 100% conversion, ~1.7 equiv) was 
transferred into the tube via a syringe. The resulting reddish brown mixture was stirred at room 
temperature for 16 h. After the reaction, the crude product was washed with EtOAc (~20 mL) and 
saturated NaHCO3 solution (~50 mL). The aqueous fraction was further washed with EtOAc (2 x ~10 
mL). The combined organic fractions were concentrated in vacuo with the aid of a rotary evaporator. 
The crude product residue was purified by preparative TLC using a solvent mixture (hexanes and 
EtOAc) as eluent to afford the isolated E-enyne product.  
 
 
General Procedure for the Nickel-Catalyzed Cross-Coupling of in-situ Formed Alkenylzinc 
Reagent with sp2-Carbon—Halogen Bond (General Procedure C). An oven-dried 30 mL re-sealable 
screw-cap test tube equipped with a Teflon-coated magnetic stir bar was charged with aryl halide / 
alkenyl halide / acyl chloride (0.41 mmol, 1.0 equiv), bis(cyclooctadiene)nickel(0) (Ni(cod)2, 11.3 mg, 
0.041 mmol, 10 mol %), and 2,2’-dipyridyl (bipy, 10 mg, 0.062 mmol, 15 mol %). The solution of in-
situ formed Z-disubstituted alkenylzinc reagent in THF/DMA (prepared in General Procedure A; ~0.7 
mmol assuming 100% conversion, ~1.7 equiv) was transferred into the tube via a syringe. The resulting 
dark mixture was stirred at 70 oC in a preheated oil bath for 16 h. After the reaction, the tube was cooled 
to room temperature, and the crude product was washed with EtOAc (~20 mL) and saturated NaHCO3 
solution (~50 mL). The aqueous fraction was further washed with EtOAc (2 x ~10 mL). The combined 
organic fractions were concentrated in vacuo with the aid of a rotary evaporator. The crude product 
residue was purified by preparative TLC using a solvent mixture (hexanes and EtOAc) as eluent to 
afford the isolated α-arylated styrene product.  
 
 
General Procedure for the Cobalt-Catalyzed Cross-Coupling of in-situ Formed Alkenylzinc 
Reagent with Alkyl Halide (General Procedure D). An oven-dried 30 mL re-sealable screw-cap test 
tube equipped with a Teflon-coated magnetic stir bar was charged with alkyl halide (0.41 mmol, 1.0 
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equiv), anhydrous cobalt(II) bromide (CoBr2, 18 mg, 0.082 mmol, 20 mol %), N,N,N’,N’-
tetramethylethylenediamine (TMEDA, 95 mg, 123 µL, 0.82 mmol,  2 equiv), and pyridine (py, 95 mg, 
99 µL, 1.23 mmol, 3 equiv). The solution of in-situ formed Z-disubstituted alkenylzinc reagent in 
THF/DMA (prepared in General Procedure A; ~0.7 mmol assuming 100% conversion, ~1.7 equiv) 
was transferred into the tube via a syringe. The resulting deep green mixture was stirred at room 
temperature for 16 h. After the reaction, the crude product was washed with EtOAc (~20 mL) and 
saturated NaHCO3 solution (~50 mL). The aqueous fraction was further washed with EtOAc (2 x ~10 
mL). The combined organic fractions were concentrated in vacuo with the aid of a rotary evaporator. 
The crude product residue was purified by preparative TLC using a solvent mixture (hexanes and 
EtOAc) as eluent to afford the isolated α-alkylated styrene product. 
 
 
General Procedure for the Cobalt-Catalyzed Cross-Coupling of in-situ Formed Alkenylzinc 
Reagent with Alkyl Halide (General Procedure E). An oven-dried 30 mL re-sealable screw-cap test 
tube equipped with a Teflon-coated magnetic stir bar was charged with alkyl halide (0.47 mmol, 1.0 
equiv), anhydrous cobalt(II) bromide (CoBr2, 20 mg, 0.094 mmol, 20 mol %), N,N,N’,N’-
tetramethylethylenediamine (TMEDA, 109 mg, 141 µL, 0.94 mmol,  2 equiv), and pyridine (py, 112 mg, 
114 µL, 1.41 mmol, 3 equiv). The solution of in-situ formed Z-disubstituted alkenylzinc reagent in 
THF/DMA (prepared in General Procedure A; ~0.7 mmol assuming 100% conversion, ~1.5 equiv) 
was transferred into the tube via a syringe. The resulting deep green mixture was stirred at room 
temperature for 16 h. After the reaction, the crude product was washed with EtOAc (~20 mL) and 
saturated NaHCO3 solution (~50 mL). The aqueous fraction was further washed with EtOAc (2 x ~10 
mL). The combined organic fractions were concentrated in vacuo with the aid of a rotary evaporator. 
The crude product residue was purified by preparative TLC using a solvent mixture (hexanes and 
EtOAc) as eluent to afford the isolated α-alkylated styrene product. 
 
 
 
 
 
(E)-N,N-Dimethyl-4-(5-methyl-1-(4-(methylthio)phenyl)hept-3-en-1-yn-3-yl)aniline (2a). Following 
the general procedure A, the alkenylzinc reagent was prepared using 4-ethynyl-N,N-dimethylaniline 
(102 mg, 0.70 mmol, 1 equiv), Zn (138 mg, 2.1 mmol, 3 equiv), TMSI (28 mg, 0.14 mmol, 20 mol %), 
and 2-iodobutane (386 mg, 2.1 mmol, 3 equiv). Following the general procedure B, the title compound 
was prepared using (4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent 
prepared in the general procedure A. The crude product was purified using hexanes/EtOAc (50:1) as an 
eluent to afford the title compound (2a) as viscous brown oil (78 mg, 55%; E:Z = 15:1). 1H NMR (400 
MHz, CDCl3): δ 7.33 (d, J = 8.3 Hz, 2 H), 7.30 (d, J = 8.7 Hz, 2 H), 7.14 (d, J = 8.3 Hz, 2 H), 6.72 (d, J 
= 8.6 Hz, 2 H), 5.94 (d, J = 10.6 Hz, 1 H), 2.96 (s, 6 H), 2.58-2.50 (m, 1 H), 2.45 (s, 3 H), 1.36 (qu, J = 
7.2 Hz, 2 H), 1.03 (d, J = 6.6 Hz, 3 H), 0.85 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 149.8, 
Me2N
SMe
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144.9, 138.5, 131.9, 129.6, 126.05, 125.96, 122.3, 120.4, 112.0, 92.5, 86.5, 40.6, 35.1, 30.4, 20.6, 15.6, 
11.9. HRMS (ESI): Calcd for C23H28NS [M]: 350.1941; Found: 350.1937.  
 
 
 
(E)-4-(3-(4-Bromophenyl)-5-methylhept-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2b). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-bromo-4-ethynylbenzene (127 mg, 
0.70 mmol, 1 equiv), Zn (138 mg, 2.1 mmol, 3 equiv), TMSI (28 mg, 0.14 mmol, 20 mol %), and 2-
iodobutane (386 mg, 2.1 mmol, 3 equiv). Following the general procedure B, the title compound was 
prepared using (4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared 
in the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (2b) as pale brown solid (112 mg, 71%; E:Z >30:1). 1H NMR (400 MHz, CDCl3): δ 7.49 (d, 
J = 8.1 Hz, 2 H), 7.32 (d, J = 8.1 Hz, 2 H), 7.25 (d, J = 8.1 Hz, 2 H), 7.14 (d, J = 8.1 Hz, 2 H), 6.04 (d, J 
= 10.7 Hz, 1 H), 2.45 (s, 3 H), 2.41-2.33 (m, 1 H), 1.38-1.30 (m, 2 H), 1.01 (d, J = 6.6 Hz, 3 H), 0.82 (t, 
J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 146.8, 139.1, 137.0, 131.8, 131.5, 130.4, 125.9, 121.6, 
121.4, 119.8, 91.1, 87.6, 35.3, 30.1, 20.5, 15.5, 12.0. HRMS (ESI): Calcd for C21H22BrS [M+H]: 
387.0602; Found: 387.0599.  
 
 
 
(E)-(4-(3-(4-Chlorophenyl)-4-cyclohexylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2c). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-chloro-4-ethynylbenzene (96 mg, 
0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and iodocyclohexane (294 mg, 1.4 mmol, 2 equiv). 
Following the general procedure B, the title compound was prepared using (4-
(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(2c) as a yellow solid (79 mg, 52%; E:Z > 30:1). 1H NMR (400 MHz, CDCl3): δ 7.36-7.31 (ovrlp, 6 H), 
7.14 (d, J = 8.4 Hz, 2 H), 6.09 (d, J = 10.5 Hz, 1 H), 2.45 (s, 3 H), 2.34-2.25 (m, 1 H), 1.73-1.61 (ovrlp, 
5 H), 1.25-1.13 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 146.3, 139.1, 136.5, 133.3, 131.8, 130.1, 
128.5, 125.9, 120.8, 119.8, 91.3, 87.5, 38.3, 32.9, 25.9, 25.5, 15.5. HRMS (ESI): Calcd for C23H24ClS 
[M]: 367.1287; Found: 367.1288.  
 
 
Br
SMe
Cl
SMe
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(E)-1-(1-Cyclohexyl-4-phenylbut-1-en-3-yn-2-yl)-4-methoxybenzene (2d). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared using 
(bromoethynyl)benzene (74 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (2d) as pale brown 
oil (81 mg, 63%; E:Z = 20:1). 1H NMR (400 MHz, CDCl3): δ 7.42 (d, J = 6.1 Hz, 2 H), 7.35 (d, J = 8.4 
Hz, 2 H), 7.29-7.24 (ovrlp, 3 H), 6.91 (d, J = 8.4 Hz, 2 H), 6.05 (d, J = 10.4 Hz, 1 H), 3.81 (s, 3 H), 
2.46-2.33 (m, 1 H), 1.75-1.60 (ovrlp, 5 H), 1.26-1.12 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 
159.0, 145.3, 131.6, 130.4, 129.9, 128.3, 127.9, 123.8, 121.3, 113.7, 92.0, 87.1, 55.4, 38.2, 33.0, 26.0, 
25.6. HRMS (ESI): Calcd for C23H25O [M+H]: 317.1906; Found: 317.1906. 
 
 
 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-fluorobenzene (2e). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) 
and iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared 
using 1-(bromoethynyl)-4-fluorobenzene (82 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(2e) as low-melting pale brown solid (80 mg, 58%; E:Z = 16:1). 1H NMR (400 MHz, CDCl3): δ 7.39 
(dd, 3JHH = 8.1 Hz, 4JHF = 5.6 Hz, 2 H), 7.34 (d, J = 8.5 Hz, 2 H), 6.97 (dd, 3JHH = 8.6 Hz, 3JHF = 8.6 Hz, 
2 H), 6.91 (d, J = 8.5 Hz, 2 H), 6.04 (d, J = 10.4 Hz, 1 H), 3.82 (s, 3 H), 2.44-2.34 (m, 1 H), 1.80-1.54 
(ovrlp, 5 H), 1.27-1.12 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 162.3 (d, 1JCF = 247.3 Hz), 159.0, 
145.4, 133.4 (d, 3JCF = 8.2 Hz), 130.3, 129.9, 121.2, 119.9 (d, 4JCF = 3.5 Hz), 115.6 (d, 2JCF = 21.9 Hz), 
113.8, 91.7, 86.0, 55.4, 38.2, 33.0, 26.0, 25.6. HRMS (ESI): Calcd for C23H24FO [M+H]: 335.1804; 
Found: 335.1806. 
 
 
 
MeO
MeO
F
MeO
CF3
	   S21 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-(trifluoromethyl)benzene (2f). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methoxybenzene (92 mg) and iodocyclohexane (221 mg). Following the general procedure B, the title 
compound was prepared using 1-(bromoethynyl)-4-(trifluoromethyl)benzene (102 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (2f) as yellow oil (122 mg, 77%; E:Z = 8.1:1). 1H NMR (400 
MHz, CDCl3): δ 7.54 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.5 Hz, 2 H), 7.34 (d, J = 8.5 Hz, 2 H), 6.93 (d, J 
= 8.5 Hz, 2 H), 6.10 (d, J = 10.4 Hz, 1 H), 3.84 (s, 3 H), 2.46-2.36 (m, 1 H), 1.75-1.60 (ovrlp, 5 H), 
1.26-1.13 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 159.1, 146.6, 131.8, 130.0, 129.9, 129.6 (q, JCF 
= 32.4 Hz), 127.7 (q, JCF = 1.3 Hz), 125.3 (q, JCF = 3.8 Hz), 124.1 (q, JCF = 270.3 Hz), 121.0, 113.9, 
94.5, 85.8, 55.4, 38.3, 33.0, 26.0, 25.6. HRMS (ESI): Calcd for C24H24F3O [M+H]: 385.1779; Found: 
385.1777.  
 
 
 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-nitrobenzene (2g). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) 
and iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared 
using 1-(bromoethynyl)-4-nitrobenzene (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes/EtOAc (50:1)  as an eluent to afford the title 
compound (2g) as viscous brown oil (66 mg, 45%; E:Z = 9.6:1). 1H NMR (400 MHz, CDCl3): δ 8.15 
(d, J = 8.6 Hz, 2 H), 7.53 (d, J = 8.6 Hz, 2 H), 7.33 (d, J = 8.5 Hz, 2 H), 6.93 (d, J = 8.6 Hz, 2 H), 6.14 
(d, J = 10.5 Hz, 1 H), 3.84 (s, 3 H), 2.47-2.36 (m, 1 H), 1.78-1.60 (ovrlp, 5 H), 1.27-1.15 (ovrlp, 5 H). 
13C NMR (100 MHz, CDCl3): δ 159.2, 147.5, 146.8, 132.2, 130.9, 129.8, 129.6, 129.7, 120.9, 113.9, 
97.6, 85.3, 55.4, 38.3, 32.9, 25.9, 25.5. HRMS (ESI): Calcd for C23H24NO3 [M+H]: 362.1756; Found: 
362.1758. 
 
 
 
(E)-1-(5-Ethyl-1-(4-methoxyphenyl)undec-3-en-1-yn-3-yl)-4-methylbenzene (2h). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) 
and 3-iodononane (267 mg). Following the general procedure B, the title compound was prepared using 
1-(bromoethynyl)-4-methoxybenzene (93 mg, 0.44 mmol, 1 equiv), CuI (13 mg, 15 mol %), bipy (14 
mg, 20 mol %), and the alkenylzinc reagent prepared in the general procedure A (~1.6 equiv). The crude 
product was purified using hexanes as an eluent to afford the title compound (2h) as a low-melting 
MeO
NO2
Me
OMe
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yellow solid (111 mg, 67%; E:Z > 50:1). 1H NMR (400 MHz, CDCl3): δ 7.35 (d, J = 8.4 Hz, 2 H), 7.27 
(d, J = 7.8 Hz, 2 H), 7.15 (d, J = 7.8 Hz, 2 H), 6.80 (d, J = 8.4 Hz, 2 H), 5.94 (d, J = 10.8 Hz, 1 H), 3.77 
(s, 3 H), 2.36-2.29 (ovrlp, 4 H), 1.48-1.12 (ovrlp, 12 H), 0.88-0.83 (ovrlp, 6 H). 13C NMR (100 MHz, 
CDCl3): δ 159.4, 144.8, 136.9, 135.7, 133.0, 128.9, 128.7, 123.8, 116.0, 113.9, 90.6, 87.2, 55.3, 40.3, 
35.4, 32.0, 29.7, 28.5, 27.4, 22.8, 21.3, 14.2, 12.0. HRMS (ESI): Calcd for C27H35O [M+H]: 375.2688; 
Found: 375.2683. 
 
 
 
(E)-4-(5-Ethyl-3-(p-tolyl)undec-3-en-1-yn-1-yl)benzonitrile (2i). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) and 3-iodononane (267 
mg). Following the general procedure B, the title compound was prepared using 4-
(bromoethynyl)benzonitrile (91 mg, 0.44 mmol, 1 equiv), CuI (13 mg, 15 mol %), bipy (14 mg, 20 mol 
%), and the alkenylzinc reagent prepared in the general procedure A (~1.6 equiv). The crude product 
was purified using hexanes/EtOAc (50:1) as an eluent to afford the title compound (2i) as viscous 
yellow oil (105 mg, 65%; E:Z > 40:1). 1H NMR (400 MHz, CDCl3): δ 7.55 (d, J = 8.2 Hz, 2 H), 7.47 
(d, J = 8.2 Hz, 2 H), 7.25 (d, J = 7.8 Hz, 2 H), 7.18 (d, J = 7.8 Hz, 2 H), 6.05 (d, J = 10.8 Hz, 1 H), 2.41-
2.31 (ovrlp, 4 H), 1.50-1.12 (ovrlp, 12 H), 0.87-0.84 (ovrlp, 6 H). 13C NMR (100 MHz, CDCl3): δ 
147.6, 137.3, 134.7, 132.0, 129.1, 128.9, 128.6, 123.1, 118.7, 111.0, 96.5, 85.8, 40.4, 35.2, 31.9, 29.6, 
28.4, 27.4, 22.8, 21.3, 14.2, 12.0. HRMS (ESI): Calcd for C27H32N [M]: 370.2528; Found: 370.2529. 
 
 
 
(E)-1-(4-(5-Butyl-3-(p-tolyl)non-3-en-1-yn-1-yl)phenyl)ethan-1-one (2j). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) and 5-
iodononane (267 mg). Following the general procedure B, the title compound was prepared using 1-(4-
(bromoethynyl)phenyl)ethan-1-one (98 mg, 0.44 mmol, 1 equiv), CuI (13 mg, 15 mol %), bipy (14 mg, 
20 mol %), and the alkenylzinc reagent prepared in the general procedure A (~1.6 equiv). The crude 
product was purified using hexanes as an eluent to afford the title compound (2j) as viscous yellow oil 
(111 mg, 65%; E:Z > 40:1). 1H NMR (400 MHz, CDCl3): δ 7.87 (d, J = 7.9 Hz, 2 H), 7.48 (d, J = 8.0 
Hz, 2 H), 7.26 (d, J = 7.6 Hz, 2 H), 7.18 (d, J = 7.5 Hz, 2 H), 6.05 (d, J = 10.8 Hz, 1 H), 2.57 (s, 3 H), 
2.46-2.40 (m, 1 H), 2.37 (s, 3 H), 1.43-1.13 (ovrlp, 12 H), 0.85 (t, J = 6.7 Hz, 6 H). 13C NMR (100 
MHz, CDCl3): δ 197.4, 147.3, 137.2, 135.9, 135.0, 131.6, 129.0, 128.9, 128.6, 128.3, 123.1, 95.5, 86.6, 
38.8, 35.4, 29.6, 26.7, 23.0, 21.3, 14.1. HRMS (ESI): Calcd for C28H35O [M+H]: 387.2688; Found: 
Me
CN
Me
O
Me
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387.2682. 
 
 
 
Methyl (E)-4-(5-Butyl-3-(p-tolyl)non-3-en-1-yn-1-yl)benzoate (2k). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) and 5-iodononane 
(267 mg). Following the general procedure B, the title compound was prepared using methyl 4-
(bromoethynyl)benzoate (105 mg, 0.44 mmol, 1 equiv), CuI (13 mg, 15 mol %), bipy (14 mg, 20 mol 
%), and the alkenylzinc reagent prepared in the general procedure A (~1.6 equiv). The crude product 
was purified using hexanes as an eluent to afford the title compound (2k) as viscous yellow oil (106 mg, 
60%; E:Z > 40:1). 1H NMR (400 MHz, CDCl3): δ 7.95 (d, J = 8.1 Hz, 2 H), 7.47 (d, J = 8.1 Hz, 2 H), 
7.26 (d, J = 7.8 Hz, 2 H), 7.17 (d, J = 7.8 Hz, 2 H), 6.04 (d, J = 10.8 Hz, 1 H), 3.89 (s, 3 H), 2.46-2.38 
(m, 1 H), 2.36 (s, 3 H), 1.42-1.12 (ovrlp, 12 H), 0.85 (t, J = 7.0 Hz, 6 H). 13C NMR (100 MHz, CDCl3): 
δ 166.7, 147.1, 137.1, 135.0, 131.4, 129.5, 129.1, 129.0, 128.68, 128.65, 123.1, 95.1, 86.6, 52.2, 38.8, 
35.4, 29.6, 23.0, 21.3, 14.1. HRMS (ESI): Calcd for C28H35O2 [M+H]: 403.2627; Found: 403.2632. 
 
 
 
(E)-4-(2-(4-(tert-Butyl)phenyl)-4-(4-(methylthio)phenyl)but-1-en-3-yn-1-yl)tetrahydro-2H-pyran 
(2l). Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg, 0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and 4-iodotetrahydro-
2H-pyran (297 mg, 1.4 mmol, 2 equiv). Following the general procedure B, the title compound was 
prepared using (4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared 
in the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (2l) as viscous pale-brown oil (103 mg, 64%; E:Z = 19:1). 1H NMR (400 MHz, CDCl3): δ 
7.40 (d, J = 7.9 Hz, 2 H), 7.34-7.32 (ovrlp, 4 H), 7.14 (d, J = 7.8 Hz, 2 H), 6.05 (d, J = 10.2 Hz, 1 H), 
3.93 (d, J = 11 Hz, 2 H), 3.38-3.32 (m, 2 H), 2.73-2.61 (m, 1 H), 2.45 (s, 3 H), 1.61-1.54 (ovrlp, 4 H), 
1.35 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 150.7, 143.1, 139.0, 134.7, 131.9, 128.3, 126.0, 125.5, 
123.1, 119.9, 91.6, 87.6, 67.3, 35.4, 34.8, 32.7, 31.5, 15.6. HRMS (ESI): Calcd for C26H31OS [M]: 
391.2096; Found: 391.2093. 
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(4-((E)-4-(Bicyclo[2.2.1]heptan-2-yl)-3-(p-tolyl)but-3-en-1-yn-1 yl)phenyl)(methyl)sulfane (2m). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and 2-
iodobicyclo[2.2.1]heptane (311 mg, 1.4 mmol, 2 equiv). Following the general procedure B, the title 
compound was prepared using (4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc 
reagent prepared in the general procedure A. The crude product was purified using hexanes as an eluent 
to afford the title compound (2m) as viscous pale-brown oil (87 mg, 59%; E:Z > 30:1). 1H NMR (400 
MHz, CDCl3): δ 7.43-7.31 (ovrlp, 4 H), 7.18 (d, J = 7.8 Hz, 2 H), 7.13 (d, J = 8.2 Hz, 2 H), 6.11 (d, J = 
10.6 Hz, 1 H), 2.44 (s, 3 H), 2.44-2.34 (ovrlp, 4 H), 2.27 (s, 1 H), 2.11 (s, 1 H), 1.55-1.47 (m, 4 H), 1.39-
1.32 (m, 1 H), 1.25-1.09 (m, 3 H). 13C NMR (100 MHz, CDCl3): δ 145.2, 138.7, 137.2, 134.9, 131.8, 
128.9, 126.0, 120.9, 120.2, 92.1, 86.9, 43.3, 41.8, 39.6, 36.7, 36.4, 29.5, 29.0, 21.3, 15.5. HRMS (ESI): 
Calcd for C25H27S [M+H]: 359.1833; Found: 359.1833. 
 
 
 
 
 
 
 
 
 
(E)-(4-(12-Chloro-3-(p-tolyl)dodec-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2n). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 
0.70 mmol, 1 equiv), Zn (138 mg, 2.1 mmol, 3 equiv), TMSI (28 mg, 0.14 mmol, 20 mol %), and 1-
chloro-8-iodooctane (577 mg, 2.1 mmol, 3 equiv), along with the additional use of CuBr2 (15 mg, 10 
mol %). Following the general procedure B, the title compound was prepared using (4-
(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(2n) as viscous brown oil (69 mg, 41%; E:Z = 9.4:1). 1H NMR (400 MHz, CDCl3): δ 7.34-7.30 (ovrlp, 
4 H), 7.19-7.14 (ovrlp, 4 H), 6.23 (t, J = 7.6 Hz, 1 H), 3.51 (t, J = 6.6 Hz, 2 H), 2.47 (s, 3 H), 2.37 (s, 3 
H), 2.25 (q, J = 7.4 Hz, 2 H), 1.74 (qu, J = 7.4 Hz, 2 H), 1.45-1.25 (ovrlp, 10 H). 13C NMR (100 MHz, 
CDCl3): δ 140.2, 138.8, 137.3, 134.9, 131.9, 129.0, 128.8, 126.0, 123.5, 120.2, 91.9, 87.0, 45.3, 32.7, 
29.8, 29.7, 29.4, 29.3, 28.9, 21.4, 15.6. HRMS (ESI): Calcd for C26H32ClS [M]: 411.1913; Found: 
411.1908. 
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Methyl(4-(5-methyl-1-(3,4,5-trimethoxyphenyl)undec-3-en-1-yn-3-yl)phenyl)sulfane (2o). 
Following the general procedure A, the alkenylzinc reagent was prepared using (4-
ethynylphenyl)(methyl)sulfane (104 mg, 0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and 2-
iodooctane (336 mg, 1.4 mmol, 2 equiv). Following the general procedure B, the title compound was 
prepared using 5-(bromoethynyl)-1,2,3-trimethoxybenzene (111 mg) and the alkenylzinc reagent 
prepared in the general procedure A. The crude product was purified using hexanes/EtOAc (100:1)  as 
an eluent to afford the title compound (2o) as viscous brown oil (97 mg, 52%; E:Z > 30:1). 1H NMR 
(400 MHz, CDCl3): δ 7.32 (d, J = 8.2 Hz, 2 H), 7.25 (d, J = 8.1 Hz, 2 H), 6.66 (s, 2 H), 6.03 (d, J = 10.6 
Hz, 1 H), 3.84 (s, 3 H), 3.83 (s, 6 H), 2.55-2.48 (ovrlp, 4 H), 1.33-1.13 (ovrlp, 10 H), 1.02 (d, J = 6.6 Hz, 
3 H), 0.86 (t, J = 6.9 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 153.1, 146.8, 138.6, 137.7, 134.9, 129.2, 
126.3, 121.7, 118.7, 108.8, 90.5, 87.4, 61.0, 56.2, 37.4, 33.6, 31.9, 29.5, 27.4, 22.8, 20.9, 15.8, 14.2. 
HRMS (ESI): Calcd for C28H37O3S [M+H]: 453.2463; Found: 453.2460.  
 
 
 
 (E)-1-Bromo-4-(3-(4-(tert-butyl)phenyl)-5,5-dimethylhex-3-en-1-yn-1-yl)benzene (2p). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene 
(126 mg, 0.80 mmol, 1 equiv), Zn (157 mg, 2.4 mmol, 3 equiv), FeBr2 (17 mg, 0.08 mmol, 10 mol %), 
TMSI (32 mg, 0.16 mmol, 20 mol %), and 2-iodo-2-methylpropane (442 mg, 2.4 mmol, 3 equiv). 
Following the general procedure B, the title compound was prepared using 1-bromo-4-
(bromoethynyl)benzene (122 mg, 0.47 mmol, 1 equiv), CuI (13.4 mg, 15 mol %), bipy (15 mg, 20 mol 
%), and the alkenylzinc reagent prepared in the general procedure A (~0.8 mmol, ~1.7 equiv). The crude 
product was purified using hexanes as an eluent to afford the title compound (2p) as yellow solid (116 
mg, 62%; E:Z > 50:1). 1H NMR (400 MHz, CDCl3): δ 7.37 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 8.2 Hz, 2 
H), 7.24-7.19 (ovrlp, 4 H), 6.27 (s, 1 H), 1.33 (s, 9 H), 0.95 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 
150.4, 150.3, 135.4, 132.9, 131.4, 128.8, 124.8, 122.8, 122.0, 121.9, 94.0, 85.9, 34.7, 34.6, 31.4, 31.0. 
HRMS (ESI): Calcd for C24H28Br [M]: 395.1375; Found: 395.1380.  
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(E)-1-(3-(4-(tert-Butyl)phenyl)-5,5-dimethylhex-3-en-1-yn-1-yl)-2-methylbenzene (2q).  Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene 
(126 mg, 0.80 mmol, 1 equiv), Zn (157 mg, 2.4 mmol, 3 equiv), FeBr2 (17 mg, 0.08 mmol, 10 mol %), 
TMSI (32 mg, 0.16 mmol, 20 mol %), and 2-iodo-2-methylpropane (442 mg, 2.4 mmol, 3 equiv). 
Following the general procedure B, the title compound was prepared using 1-(bromoethynyl)-2-
methylbenzene (92 mg, 0.47 mmol, 1 equiv), CuI (13.4 mg, 15 mol %), bipy (15 mg, 20 mol %), and the 
alkenylzinc reagent prepared in the general procedure A (~0.8 mmol, ~1.7 equiv). The crude product 
was purified using hexanes as an eluent to afford the title compound (2q) as viscous yellow oil (94 mg, 
60%; E:Z > 50:1). 1H NMR (400 MHz, CDCl3): δ 7.35-7.31 (ovrlp, 3 H), 7.25 (d, J = 8.2 Hz, 2 H), 
7.15-7.10 (ovrlp, 2 H), 7.09-7.04 (m, 1 H), 6.25 (s, 1 H), 2.35 (s, 3 H), 1.33 (s, 9 H), 0.97 (s, 9 H). 13C 
NMR (100 MHz, CDCl3): δ 150.2, 149.4, 140.1, 136.0, 131.7, 129.4, 128.8, 127.9, 125.5, 124.8, 123.6, 
122.6, 97.1, 86.2, 34.69, 34.68, 31.6, 21.2, 20.8. HRMS (ESI): Calcd for C25H31 [M+H]: 331.2420; 
Found: 331.2420. 
 
 
 
 
 
 
 
 
 
 
(4-((E)-4-(Adamantan-1-yl)-3-(4-methoxyphenyl)but-3-en-1-yn-1 yl)phenyl)(methyl)sulfane (2r). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methoxybenzene (53 mg, 0.40 mmol, 1 equiv), Zn (131 mg, 2.0 mmol, 5 equiv), FeBr2 (9 mg, 10 mol 
%), TMSI (24 mg, 0.12 mmol, 30 mol %), 1-iodoadamantane (524 mg, 2.0 mmol, 5 equiv), and DMA 
(0.8 mL), and the reaction mixture was stirred at room temperature for 4 d. THF (4.5 mL) was then 
added into the reaction mixture to form an in-situ alkenylzinc reagent. Following the general procedure 
B, the title compound was prepared using (4-(bromoethynyl)phenyl)(methyl)sulfane (54.5 mg, 0.24 
mmol, 1 equiv), CuI (6.8 mg, 15 mol %), bipy (7.5 mg, 20 mol %), and the alkenylzinc reagent prepared 
in the general procedure A (~0.4 mmol, ~1.7 equiv). The crude product was purified using hexanes as an 
eluent to afford the title compound (2r) as a white solid (54 mg, 54%; E:Z > 50:1). 1H NMR (400 MHz, 
CDCl3): δ 7.27 (d, J = 8.1 Hz, 2 H), 7.22 (d, J = 8.3 Hz, 2 H), 7.11 (d, J = 8.1 Hz, 2 H), 6.85 (d, J = 8.3 
Hz, 2 H), 6.00 (s, 1 H), 3.82 (s, 3 H), 2.44 (s, 3 H), 1.88-1.82 (m, 3 H), 1.62-1.52 (ovrlp, 12 H). 13C 
NMR (100 MHz, CDCl3): δ 158.8, 150.3, 138.6, 131.8, 131.5, 130.3, 125.9, 121.7, 120.3, 113.3, 93.4, 
86.8, 55.3, 42.8, 37.3, 36.7, 28.5, 15.6. HRMS (ESI): Calcd for C28H31OS [M+H]: 415.2088; Found: 
415.2090. 
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Methyl (E)-4-(4-(tert-Butyl)phenyl)-5-cyclohexylpent-4-en-2-ynoate (2s). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg) and 
iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared using 
methyl 3-bromopropiolate (67 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (2s) as viscous 
brown oil (64 mg, 48%; E:Z > 30:1). 1H NMR (400 MHz, CDCl3): δ 7.42 (d, J = 8.2 Hz, 2 H), 7.30 (d, 
J = 8.2 Hz, 2 H), 6.33 (d, J = 10.6 Hz, 1 H), 3.80 (s, 3 H), 2.57-2.45 (m, 1 H), 1.80-1.64 (ovrlp, 5 H), 
1.37 (s, 9 H), 1.29-1.16 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 154.7, 151.9, 151.0, 132.8, 128.3, 
125.5, 119.3, 89.4, 78.3, 52.7, 38.4, 34.8, 32.5, 31.4, 25.8, 25.3. HRMS (ESI): Calcd for C22H29O2 
[M+H]: 325.2168; Found: 325.2168.  
 
 
 
(E)-4-(4-(tert-Butyl)phenyl)-5-cyclohexyl-1-morpholinopent-4-en-2-yn-1-one (2t). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 
mg) and iodocyclohexane (221 mg). Following the general procedure B, the title compound was 
prepared using 3-bromo-1-morpholinoprop-2-yn-1-one (89 mg) and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes/EtOAc (50:1) as an eluent to 
afford the title compound (2t) as viscous yellow oil (104 mg, 67%; E:Z = 12:1). 1H NMR (400 MHz, 
CDCl3): δ 7.38 (d, J = 8.0 Hz, 2 H), 7.26 (d, J = 8.1 Hz, 2 H), 6.22 (d, J = 10.6 Hz, 1 H), 3.72-3.67 (m, 4 
H), 3.66-3.62 (ovrlp, 4 H), 2.50-2.41 (m, 1 H), 1.76-1.61 (ovrlp, 5 H), 1.34 (s, 9 H), 1.34-1.14 (ovrlp, 5 
H). 13C NMR (100 MHz, CDCl3): δ 153.5, 150.8, 150.2, 133.2, 128.1, 125.4, 119.6, 93.9, 78.6, 66.9, 
66.5, 47.2, 41.9, 38.2, 34.6, 32.6, 31.3, 25.8, 25.2. HRMS (ESI): Calcd for C25H34NO2 [M+H]: 
380.2589; Found: 380.2592. 
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(E)-(4-((6-(4-(tert-Butyl)phenyl)-7-cyclohexylhept-6-en-4-yn-1-yl)oxy)phenyl)(phenyl)methanone 
(2u). Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg) and iodocyclohexane (221 mg). Following the general procedure B, the title 
compound was prepared using (4-((5-bromopent-4-yn-1-yl)oxy)phenyl)(phenyl)methanone (141 mg), 
CuI (20 mg, 25 mol %), bipy (22 mg, 35 mol %), and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(2u) as viscous yellow oil (115 mg, 56%; E:Z = 18:1). 1H NMR (400 MHz, CDCl3): δ 7.81 (d, J = 8.3 
Hz, 2 H), 7.75 (d, J = 7.4 Hz, 2 H), 7.55 (t, J = 7.1 Hz, 1 H), 7.46 (t, J = 7.3 Hz, 2 H), 7.33 (d, J = 8.1 
Hz, 2 H), 7.27 (d, J = 7.8 Hz, 2 H), 6.95 (d, J = 8.3 Hz, 2 H), 4.15 (t, J = 5.9 Hz, 2 H), 2.55 (t, J = 6.6 
Hz, 2 H), 2.42-2.31 (m, 1 H), 2.04 (qu, J = 6.3 Hz, 2 H), 1.74-1.58 (ovrlp, 5 H), 1.31 (s, 9 H), 1.22-1.08 
(ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 195.6, 162.8, 150.2, 144.5, 138.4, 135.3, 132.6, 131.9, 
130.1, 129.8, 128.3, 128.2, 125.1, 121.5, 114.2, 86.1, 83.9, 66.8, 37.9, 34.6, 33.1, 31.4, 28.4, 26.0, 25.5, 
16.2.  HRMS (ESI): Calcd for C36H41O2 [M+H]: 505.3099; Found: 505.3101. 
 
 
 
(E)-2-(4-Cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)naphthalene (2v). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1 ethynylbenzene (72 mg) and iodocyclohexane (221 
mg). Following the general procedure B, the title compound was prepared using 2-
(bromoethynyl)naphthalene (95 mg) and the alkenylzinc reagent prepared in the general procedure A. 
The crude product was purified using hexanes as an eluent to afford the title compound (2v) as viscous 
brown oil (75 mg, 54%; E:Z > 30:1). 1H NMR (400 MHz, CDCl3): δ 7.94 (s, 1 H), 7.78-7.72 (ovrlp, 3 
H), 7.49-7.43 (ovrlp, 5 H), 7.40 (t, J = 7.6 Hz, 2 H), 7.31 (t, J = 7.3 Hz, 1 H), 6.17 (d, J = 10.5 Hz, 1 H), 
2.45-2.36 (m, 1 H), 1.73-1.60 (ovrlp, 5 H), 1.26-1.16 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 
146.3, 138.1, 133.2, 132.7, 131.3, 128.8, 128.6, 128.4, 128.0, 127.85, 127.81, 127.5, 126.6, 122.0, 121.1, 
38.2, 33.0, 26.0, 25.6. HRMS (ESI): Calcd for C26H24 [M]: 336.1878; Found: 336.1869.  
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(E)-1-Chloro-4-(4-cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)benzene (2w). Following the general 
procedure A, the alkenylzinc reagent was prepared using ethynylbenzene (72 mg) and iodocyclohexane 
(221 mg). Following the general procedure B, the title compound was prepared using 1-(bromoethynyl)-
4-chlorobenzene (88 mg), CuI (16 mg, 20 mol %), bipy (19 mg, 30 mol %), and the alkenylzinc reagent 
prepared in the general procedure A. The crude product was purified using hexanes as an eluent to 
afford the title compound (2w) as yellow solid (74 mg, 57%; E:Z > 20:1). 1H NMR (400 MHz, CDCl3): 
δ 7.41-7.30 (ovrlp, 7 H), 7.24 (d, J = 8.2 Hz, 2 H), 6.11 (d, J = 10.4 Hz, 1 H), 2.43-2.32 (m, 1 H), 1.77-
1.58 (ovrlp, 5 H), 1.28-1.10 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 146.5, 137.8, 133.9, 132.8, 
128.69, 128.66, 128.4, 127.6, 122.3, 121.7, 92.7, 86.3, 38.2, 33.0, 26.0, 25.5. HRMS (ESI): Calcd for 
C22H22Cl [M+H]: 321.1410; Found: 321.1407. 
 
 
 
(E)-(4-Cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)triethylsilane (2x). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1 ethynylbenzene (72 mg) and iodocyclohexane (221 mg). 
Following the general procedure B, the title compound was prepared using (bromoethynyl)triethylsilane 
(90 mg), CuI (16 mg, 20 mol %), bipy (19 mg, 30 mol %), and the alkenylzinc reagent prepared in the 
general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (2x) as colorless oil (85 mg, 64%; E:Z = 9.9:1). 1H NMR (400 MHz, CDCl3): δ 7.38-7.32 
(ovrlp, 4 H), 7.26 (t, J = 7.3 Hz, 1 H), 6.06 (d, J = 10.5 Hz, 1 H), 2.39-2.31 (m, 1 H), 1.78-1.58 (ovrlp, 5 
H), 1.23-1.13 (ovrlp, 5 H), 0.99 (t, J = 7.9 Hz, 9 H), 0.61 (d, J = 7.9 Hz, 6 H). 13C NMR (100 MHz, 
CDCl3): δ 146.6, 137.9, 128.7, 128.2, 127.4, 122.1, 108.2, 89.0, 38.1, 33.0, 26.0, 25.8, 7.7, 4.7. HRMS 
(ESI): Calcd for C22H33Si [M]: 325.2351; Found: 325.2348. 
 
 
 
(E)-3-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-9-ethyl-9H-carbazole (2y). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 
Cl
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mg) and iodocyclohexane (221 mg). Following the general procedure B, the title compound was 
prepared using 3-(bromoethynyl)-9-ethyl-9H-carbazole (122 mg) and the alkenylzinc reagent prepared 
in the general procedure A. The crude product was purified using hexanes/EtOAc (100:1) as an eluent to 
afford the title compound (2y) as viscous brown oil (119 mg, 67%; E:Z > 20:1). 1H NMR (400 MHz, 
CDCl3): δ 8.19 (s, 1 H), 8.02 (d, J = 7.7 Hz, 1 H), 7.52 (d, J = 8.4 Hz, 1 H), 7.45-7.40 (ovrlp, 3 H), 7.33 
(d, J = 8.1 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 H), 7.20 (d, J = 7.4 Hz, 1 H), 6.93 (d, J = 8.2 Hz, 2 H), 6.08 
(d, J = 10.4 Hz, 1 H), 4.25 (q, J = 7.1 Hz, 2 H), 3.80 (s, 3 H), 2.46-2.37 (m, 1 H), 1.76-1.59 (ovrlp, 5 H), 
1.36 (t, J = 7.1 Hz, 3 H), 1.26-1.13 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 158.9, 144.3, 140.3, 
139.4, 130.9, 129.9, 129.3, 126.1, 124.0, 123.0, 122.6, 121.7, 120.6, 119.3, 113.8, 113.7, 108.7, 108.4, 
90.1, 88.5, 55.3, 38.2, 37.7, 33.2, 26.0, 25.6, 13.9. HRMS (ESI): Calcd for C31H32NO [M]: 434.2484; 
Found: 434.2481. 
 
 
 
(E)-5-Cyclohexyl-4-(4-methoxyphenyl)-1-phenylpent-4-en-2-yn-1-one (2z). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared using 
3-bromo-1-phenylprop-2-yn-1-one (86 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(2z) as viscous brown oil (69 mg, 49%; E:Z = 8.7:1). 1H NMR (400 MHz, CDCl3): δ 8.11 (d, J = 7.6 
Hz, 2 H), 7.58 (t, J = 6.8 Hz, 1 H), 7.46 (d, J = 7.5 Hz, 2 H), 7.34 (d, J = 8.4 Hz, 2 H), 6.94 (d, J = 8.4 
Hz, 2 H), 6.39 (d, J = 10.5 Hz, 1 H), 3.84 (s, 3 H), 2.53-2.42 (m, 1 H), 1.80-1.58 (ovrlp, 5 H), 1.31-1.13 
(ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 178.1, 159.4, 152.0, 137.2, 139.9, 129.9, 129.6, 128.6, 
128.5, 119.8, 114.0, 96.3, 85.3, 55.4, 38.6, 32.6, 25.8, 25.4. HRMS (ESI): Calcd for C24H25O2 [M+H]: 
345.1855; Found: 345.1855. 
 
 
 
 (E)-2-((6-Cyclohexyl-5-(4-methoxyphenyl)hex-5-en-3-yn-1-yl)oxy)tetrahydro-2H-pyran (2aa). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methoxybenzene (92 mg) and iodocyclohexane (221 mg). Following the general procedure B, the title 
compound was prepared using 2-((4-bromobut-3-yn-1-yl)oxy)tetrahydro-2H-pyran (96 mg), CuI (20 
mg, 25 mol %), bipy (22 mg, 35 mol %), and the alkenylzinc reagent prepared in the general procedure 
A. The crude product was purified using hexanes/EtOAc (50:1) as an eluent to afford the title compound 
(2aa) as viscous yellow oil (82 mg, 54%; E:Z = 16:1). 1H NMR (400 MHz, CDCl3): δ 7.27 (d, J = 8.6 
MeO O
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Hz, 2 H), 6.87 (d, J = 8.6 Hz, 2 H), 5.87 (d, J = 10.4 Hz, 1 H), 4.64 (t, J = 3.0 Hz, 1 H), 3.88-3.79 (ovrlp, 
5 H), 3.60-3.54 (m, 1 H), 3.50-3.45 (m, 1 H), 2.62 (d, J = 7.2 Hz, 2 H), 2.35-2.28 (m, 1 H), 1.85-1.46 
(ovrlp, 11 H), 1.21-1.07 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 158.8, 144.1, 130.8, 129.8, 121.3, 
113.6, 98.7, 84.4, 83.9, 65.9, 62.2, 55.3, 37.9, 33.1, 30.7, 26.0, 25.57, 25.56, 21.0, 19.5. HRMS (ESI): 
Calcd for C24H33O3 [M]: 369.2430; Found: 369.2432. 
 
 
 
(E)-1-(tert-Butyl)-4-(4-cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)benzene (S2a). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 
mg) and iodocyclohexane (221 mg). Following the general procedure B, the title compound was 
prepared using 1-(bromoethynyl)-4-(tert-butyl)benzene (97 mg) and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (S2a) as viscous yellow oil (67 mg, 44%; E:Z = 17:1). 1H NMR (400 MHz, CDCl3): δ 7.36-
7.35 (ovrlp, 4 H), 7.30 (d, J = 8.2 Hz, 2 H), 6.90 (d, J = 8.4 Hz, 2 H), 6.03 (d, J = 10.4 Hz, 1 H), 3.82 (s, 
3 H), 2.44-2.36 (ovrlp, 1 H), 1.77-1.57 (ovrlp, 5 H), 1.29 (s, 9 H), 1.25-1.12 (ovrlp, 5 H). 13C NMR (100 
MHz, CDCl3): δ 158.9, 151.1, 144.9, 131.3, 130.6, 129.9, 125.3, 121.5, 120.8, 113.7, 91.4, 87.3, 55.4, 
38.2, 34.8, 33.1, 31.3, 26.0, 25.6.  
 
 
 
(E)-(4-(3-(4-(tert-Butyl)phenyl)-4-cycloheptylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (S2b). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg, 0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and iodocycloheptane 
(314 mg, 1.4 mmol, 2 equiv). Following the general procedure B, the title compound was prepared using 
(4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(S2b) as viscous brown oil (71 mg, 43%; E:Z > 40:1). 1H NMR (400 MHz, CDCl3): δ 7.42-7.30 (ovrlp, 
6 H), 7.14 (d, J = 8.1 Hz, 2 H), 6.17 (d, J = 10.8 Hz, 1 H), 2.65-2.56 (m, 1 H), 2.45 (s, 3 H), 1.79-1.64 
(m, 4 H), 1.59-1.40 (ovrlp, 8 H), 1.34 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 150.3, 146.3, 138.7, 
134.9, 131.9, 128.5, 126.0, 125.2, 120.3, 120.2, 92.3, 86.7, 39.2, 34.9, 34.7, 31.5, 28.7, 26.2, 15.6.  
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(E)-(4-(3-(4-(tert-Butyl)phenyl)-4-cyclooctylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (S2c). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg, 0.70 mmol, 1 equiv), Zn (92 mg, 1.4 mmol, 2 equiv), and iodocyclooctane 
(333 mg, 1.4 mmol, 2 equiv). Following the general procedure B, the title compound was prepared using 
(4-(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(S2c) as viscous brown oil (78 mg, 46%; E:Z > 20:1). 1H NMR (400 MHz, CDCl3): δ 7.40-4.32 (ovrlp, 
6 H), 7.14 (d, J = 8.0 Hz, 2 H), 6.18 (d, J = 10.8 Hz, 1 H), 2.71-2.63 (m, 1 H), 2.45 (s, 3 H), 1.73-1.63 
(ovrlp, 4 H), 157-1.42 (ovrlp, 10 H), 1.34 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 150.3, 146.4, 138.7, 
134.9, 131.9, 128.5, 126.0, 125.2, 120.31, 120.27, 92.3, 86.7, 37.4, 34.7, 32.1, 31.5, 27.4, 26.2, 25.0, 
15.6.   
 
 
 
(E)-Methyl(4-(5-methyl-7-phenyl-3-(p-tolyl)hept-3-en-1-yn-1-yl)phenyl)sulfane (S2d). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 
mg, 0.70 mmol, 1 equiv), Zn (137 mg, 2.1 mmol, 3 equiv), and (3-iodobutyl)benzene (546 mg, 2.1 
mmol, 3 equiv). Following the general procedure B, the title compound was prepared using (4-
(bromoethynyl)phenyl)(methyl)sulfane (93 mg) and the alkenylzinc reagent prepared in the general 
procedure A. The crude product was purified using hexanes as an eluent to afford the title compound 
(S2d) as viscous pale-brown oil (93 mg, 39%; E:Z = 18:1). 1H NMR (400 MHz, CDCl3): δ 7.34 (d, J = 
8.2 Hz, 2 H), 7.26 (d, J =7.8 Hz, 2 H), 7.21-7.11 (ovrlp, 7 H), 7.05 (d, J =7.3 Hz, 2 H), 6.06 (d, J =10.6 
Hz, 1 H), 2.64-2.56 (m, 2 H), 2.49-2.42 (ovrlp, 4 H), 2.36 (s, 3 H), 1.63 (q, J =7.6 Hz, 2 H), 1.07 (d, J = 
6.5 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 145.6, 142.4, 138.9, 137.2, 135.1, 131.9, 129.1, 128.6, 
128.5, 128.3, 126.0, 125.7, 123.0, 120.1, 91.8, 87.3, 39.4, 33.8, 33.2, 21.4, 21.0, 15.5.  
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(E)-2-(5-Cyclohexyl-4-(4-methoxyphenyl)pent-4-en-2-yn-1-yl)isoindoline-1,3-dione (S2e). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methoxybenzene (92 mg) and iodocyclohexane (221 mg). Following the general procedure B, the title 
compound was prepared using 2-(3-bromoprop-2-yn-1-yl)isoindoline-1,3-dione (117 mg), CuI (20 mg, 
25 mol %), bipy (22 mg, 35 mol %), and the alkenylzinc reagent prepared in the general procedure A. 
The crude product was purified using hexanes/EtOAc (50:1) as an eluent to afford the title compound 
(S2e) as low-melting yellow solid (67 mg, 41%; E:Z = 17:1). 1H NMR (400 MHz, CDCl3): δ 7.90-7.84 
(m, 2 H), 7.74-7.69 (m, 2 H), 7.25 (d, J = 8.6 Hz, 2 H), 6.86 (d, J = 8.5 Hz, 2 H), 5.94 (d, J = 10.5 Hz, 1 
H), 4.58 (s, 2 H), 3.80 (s, 3 H), 2.36-2.27 (m, 1 H), 1.72-1.57 (ovrlp, 5 H), 1.24-1.07 (ovrlp, 5 H). 13C 
NMR (100 MHz, CDCl3): δ 167.2, 158.9, 145.9, 134.2, 132.2, 130.0, 129.8, 123.5, 120.4, 113.6, 85.4, 
80.1, 55.3, 38.0, 32.9, 28.0, 25.9, 25.5.  
 
 
 
(E)-1-Chloro-4-((8-cyclohexyl-7-(4-methoxyphenyl)oct-7-en-5-yn-1-yl)oxy)benzene (S2f). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 
mg) and iodocyclohexane (221 mg). Following the general procedure B, the title compound was 
prepared using 1-((6-bromohex-5-yn-1-yl)oxy)-4-chlorobenzene (118 mg), CuI (20 mg, 25 mol %), bipy 
(22 mg, 35 mol %), and the alkenylzinc reagent prepared in the general procedure A. The crude product 
was purified using hexanes as an eluent to afford the title compound (S2f) as viscous yellow oil (86 mg, 
49%; E:Z = 18:1). 1H NMR (400 MHz, CDCl3): δ 7.27 (d, J = 8.4 Hz, 2 H), 7.20 (d, J = 8.6 Hz, 2 H), 
6.87 (d, J = 8.4 Hz, 2 H), 6.79 (d, J = 8.6 Hz, 2 H), 5.85 (d, J = 10.4 Hz, 1 H), 3.93 (t, J = 6.2 Hz, 2 H), 
3.80 (s, 3 H), 2.39 (d, J = 6.9 Hz, 2 H), 2.35-2.27 (m, 1 H), 1.89 (qu, J = 7.6 Hz, 2 H), 1.74-1.56 (ovrlp, 
7 H), 1.24-1.08 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 158.8, 157.7, 143.9, 131.0, 129.7, 129.4, 
125.5, 121.4, 115.8, 113.6, 87.1, 83.5, 67.8, 55.3, 38.0, 33.1, 28.5, 26.0, 25.6, 25.4, 19.3.  
 
 
 
(E)-7-Cyclohexyl-6-(4-methoxyphenyl)hept-6-en-4-yn-1-yl 4-chlorobenzoate (S2g). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) 
and iodocyclohexane (221 mg). Following the general procedure B, the title compound was prepared 
using 5-bromopent-4-yn-1-yl 4-chlorobenzoate (124 mg), CuI (20 mg, 25 mol %), bipy (22 mg, 35 mol 
%), and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes as an eluent to afford the title compound (S2g) as viscous yellow oil (80 mg, 44%; E:Z = 
16:1). 1H NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.3 Hz, 2 H), 7.39 (d, J = 8.3 Hz, 2 H), 7.26 (d, J = 
MeO O
Cl
MeO O
O
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8.3 Hz, 2 H), 6.87 (d, J = 8.4 Hz, 2 H), 5.86 (d, J = 10.4 Hz, 1 H), 4.42 (t, J = 6.2 Hz, 2 H), 3.81 (s, 3 H), 
2.51 (t, J = 7.0 Hz, 2 H), 2.34-2.27 (m, 1 H), 2.00 (qu, J = 6.6 Hz, 2 H), 1.74-1.57 (ovrlp, 5 H), 1.20-
1.08 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 165.8, 158.8, 144.2, 139.5, 131.1, 130.8, 129.7, 
128.9, 128.8, 121.2, 113.6, 86.0, 83.8, 64.2, 55.4, 38.0, 33.1, 28.1, 26.0, 25.6, 16.5.  
 
 
 
(E)-6-Methyl-4-(4-(methylthio)phenyl)dodec-4-en-2-yn-1-yl benzoate (S2h). Following the general 
procedure A, the alkenylzinc reagent was prepared using (4-ethynylphenyl)(methyl)sulfane (104 mg) 
and 2-iodooctane (252 mg). Following the general procedure B, the title compound was prepared using 
3-bromoprop-2-yn-1-yl benzoate (98 mg) and the alkenylzinc reagent prepared in the general procedure 
A. The crude product was purified using hexanes as an eluent to afford the title compound (S2h) as 
viscous yellow oil (64 mg, 37%; E:Z > 20:1). 1H NMR (400 MHz, CDCl3): δ 8.07 (d, J =7.7 Hz, 2 H), 
7.56 (t, J =7.2 Hz, 1 H), 7.44 (t, J =7.6 Hz, 2 H), 7.27-7.22 (ovrlp, 4 H), 6.00 (d, J =10.7 Hz, 1 H), 5.06 
(s, 2 H), 2.51-2.43 (ovrlp, 4 H), 1.30-1.13 (ovrlp, 10 H), 0.98 (d, J =6.5 Hz, 3 H), 0.85 (d, J =6.4 Hz, 3 
H). 13C NMR (100 MHz, CDCl3): δ 166.1, 148.0, 137.8, 134.4, 133.3, 129.9, 129.8, 129.1, 128.5, 126.4, 
120.9, 88.6, 80.9, 53.6, 37.3, 33.5, 31.9, 29.5, 27.4, 22.8, 20.8, 15.9, 14.2.  
 
 
 
Ethyl (E)-3-(2-Cyclohexyl-1-(p-tolyl)vinyl)benzoate (3a). Following the general procedure A, the 
alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) and iodocyclohexane (221 
mg). Following the general procedure C, the title compound was prepared using ethyl 3-iodobenzoate 
(113 mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was 
purified using hexanes as an eluent to afford the title compound (3a) as viscous brown oil (88 mg, 62%). 
1H NMR (400 MHz, CDCl3): δ 7.98 (s, 1 H), 7.89-7.85 (m, 1 H), 7.27-7.25 (ovrlp, 2 H), 7.16 (d, J = 7.6 
Hz, 2 H), 7.05 (d, J = 8 Hz, 2 H), 5.92 (d, J = 10.0 Hz, 1 H), 4.37 (qu, J = 7.2 Hz, 2 H), 2.38 (s, 3 H), 
2.26-2.11 (m, 1 H), 1.77-1.59 (ovrlp, 5 H), 1.28 (t, J = 6.8 Hz, 3 H), 1226-1.17 (ovrlp, 5 H). 13C NMR 
(100 MHz, CDCl3): δ 167.0, 143.8, 138.9, 137.2, 137.0, 136.7, 132.2, 130.5, 129.7, 129.1, 128.12, 
128.08, 127.8, 61.1, 38.5, 33.4, 26.1, 25.7, 21.4, 14.5. HRMS (ESI): Calcd for C24H29O2 [M]: 349.2168; 
Found: 349.2159. 
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4,4'-(2-Cyclohexylethene-1,1-diyl)bis(methylbenzene) (3b). Following the general procedure A, the 
alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg) and iodocyclohexane (221 
mg). Following the general procedure C, the title compound was prepared using 1-iodo-4-
methylbenzene (89 mg) and the alkenylzinc reagent prepared in the general procedure A. The crude 
product was purified using hexanes as an eluent to afford the title compound (3b) as white solid (74 mg, 
62%). 1H NMR (400 MHz, CDCl3): δ 7.14 (d, J = 7.8 Hz, 2 H), 7.08 (d, J = 8.1 Hz, 2 H), 7.06-7.03 
(ovrlp, 4 H), 5.81 (d, J = 10.0 Hz, 1 H), 2.38 (s, 3 H), 2.30 (s, 3 H), 2.16-2.13 (m, 1 H), 1.66-1.59 (ovrlp, 
5 H), 1.22-1.15 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 140.6, 139.4, 137.9, 136.4, 136.3, 135.2, 
129.8, 128.9, 128.8, 127.3, 38.4, 33.6, 26.2, 25.8, 21.4, 21.2. HRMS (ESI): Calcd for C22H27 [M+H]: 
291.2113; Found: 291.2110. 
 
 
 
Ethyl (E)-4-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)benzoate (3c). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
ethyl 4-bromobenzoate (94 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (3c) as viscous 
brown oil (97 mg, 61%). 1H NMR (400 MHz, CDCl3): δ 7.92 (d, J = 8.2 Hz, 2 H), 7.38 (d, J = 8.0 Hz, 2 
H), 7.26 (d, J = 8.2 Hz, 2 H), 7.07 (d, J = 8.1 Hz, 2 H), 5.96 (d, J = 10.1 Hz, 1 H), 4.34 (q, J = 7.1 Hz, 2 
H), 7.27-2.17 (m, 1 H), 1.74-1.58 (ovrlp, 5 H), 1.36 (s, 9 H), 1.26-1.13 (ovrlp, 5 H). 13C NMR (100 
MHz, CDCl3): δ 166.8, 150.0, 148.0, 139.1, 138.0, 136.9, 129.5, 129.4, 128.6, 127.3, 125.2, 60.9, 38.5, 
34.8, 33.4, 31.6, 26.1, 25.7, 14.5. HRMS (ESI): Calcd for C27H35O2 [M]: 391.2637; Found: 391.2639. 
 
 
 
Ethyl (E)-5-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)thiophene-2-carboxylate (3d). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 
mg) and iodocyclohexane (221 mg). Following the general procedure C, the title compound was 
Me Me
t-Bu
O
OEt
t-Bu S
CO2Et
	   S36 
prepared using ethyl 5-bromothiophene-2-carboxylate (96 mg), Ni(cod)2 (17 mg, 15 mol %), bipy (16 
mg, 25 mol %), and the alkenylzinc reagent prepared in the general procedure A. The crude product was 
purified using hexanes as an eluent to afford the title compound (3d) as viscous brown oil (86 mg, 53%). 
1H NMR (400 MHz, CDCl3): δ 7.56 (d, J = 3.7 Hz, 1 H), 7.39 (d, J = 8.0 Hz, 2 H), 7.14 (d, J = 7.9 Hz, 
2 H), 6.60 (d, J = 3.7 Hz, 1 H), 6.09 (d, J = 10.0 Hz, 1 H), 4.31 (q, J = 7.1 Hz, 2 H), 2.15-2.00 (m, 1 H), 
1.70-1.59 (ovrlp, 5 H), 1.42-1.29 (ovrlp, 12 H), 1.23-1.11 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 
162.6, 154.8, 150.5, 137.4, 135.6, 133.68, 133.66, 130.9, 129.1, 125.3, 125.0, 38.2, 34.7, 33.1, 31.5, 
26.0, 25.5, 14.5. HRMS (ESI): Calcd for C25H33O2S [M+H]: 397.2196; Found: 397.2193.  
 
 
 
(E)-1-(3-Methyl-1-(p-tolyl)pent-1-en-1-yl)-3-(trifluoromethyl)benzene (3e). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using 1-iodo-3-
(trifluoromethyl)benzene (112 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (3e) as viscous 
colorless oil (85 mg, 65%). 1H NMR (400 MHz, CDCl3): δ 7.51 (s, 1 H), 7.44-7.41 (m, 1 H), 7.35-7.29 
(ovrlp, 2 H), 7.18 (d, J = 7.7 Hz, 2 H), 7.04 (d, J = 7.9 Hz, 2 H), 5.87 (d, J = 10.2 Hz, 1 H), 2.38 (s, 3 H), 
2.30-2.19 (m, 1 H), 1.36 (qu, J = 7.3 Hz, 2 H), 1.01 (d, J = Hz, 2 H), 1.01 (d, J = 6.6 Hz, 3 H), 0.84 (t, J 
= 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ144.0, 139.4, 137.8, 136.9, 130.7, 130.6 (q, J = 31.7 
Hz), 129.8, 129.2, 128.6, 124.4 (q, J = 270.8 Hz), 123.6 (q, J = 3.8 Hz), 123.4 (q, J = 3.7 Hz), 35.7, 
30.5, 21.4, 21.0, 12.2. GCMS: [M]+ = 318 was detected which corresponds to  C20H21F3.  
 
 
 
(Z)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-N,N-diethylbenzamide (3f). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
4-bromo-N,N-diethylbenzamide (105 mg) and the alkenylzinc reagent prepared in the general procedure 
A. The crude product was purified using hexanes as an eluent to afford the title compound (3f) as low-
melting yellow solid (98 mg, 61%). 1H NMR (400 MHz, CDCl3): δ 7.27-7.21 (ovrlp, 4 H), 7.05 (d, J = 
8.4 Hz, 2 H), 6.92 (d, J = 8.8 Hz, 2 H), 5.91 (d, J = 10.0 Hz, 1 H), 3.83 (s, 3 H), 3.52 (br s, 2 H), 3.28 (br 
s, 2 H), 2.27-2.10 (m, 1 H), 1.80-1.55 (ovrlp, 5 H), 1.38-1.17 (ovrlp, 11 H). 13C NMR (100 MHz, 
CDCl3): δ 171.3, 158.6, 144.2, 138.7, 136.6, 135.5, 132.5, 130.9, 127.2, 126.2, 113.6, 55.2, 43.3, 39.4, 
Me
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38.4, 33.4, 26.0, 25.7, 14.3, 13.1. HRMS (ESI): Calcd for C26H34NO2 [M+H]: 392.2584; Found: 
392.2584.  
 
 
 
(E)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-2-methylbenzonitrile (3g). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
4-bromo-2-methylbenzonitrile (76 mg) and the alkenylzinc reagent prepared in the general procedure A. 
The crude product was purified using hexanes/EtOAc (100:1) as an eluent to afford the title compound 
(3g) as low-melting colorless solid (76 mg, 56%). 1H NMR (400 MHz, CDCl3): δ 7.44 (d, J = 8.1 Hz, 1 
H), 7.13 (s, 1 H), 7.07 (d, J = 8.2 Hz, 1 H), 7.04 (d, J = 8.4 Hz, 2 H), 6.93 (d, J = 8.3 Hz, 2 H), 5.95 (d, J 
= 10.0 Hz, 1 H), 3.84 (s, 3 H), 2.47 (s, 3 H), 2.26-2.16 (m, 1 H), 1.68-1.61 (ovrlp, 5 H), 1.26-1.16 (ovrlp, 
5 H). 13C NMR (100 MHz, CDCl3): δ 158.8, 147.8, 141.6, 138.8, 138.3, 132.3, 131.7, 130.9, 128.9, 
125.2, 118.6, 113.9, 110.5, 55.3, 38.6, 33.2, 26.0, 25.6, 20.6. HRMS (ESI): Calcd for C23H26NO [M]: 
332.2009; Found: 332.2009. 
 
 
 
(Z)-1-(4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)phenyl)ethan-1-one (3h). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
1-(4-iodophenyl)ethan-1-one (101 mg) and the alkenylzinc reagent prepared in the general procedure A. 
The crude product was purified using hexanes as an eluent to afford the title compound (3h) as viscous 
pale-yellow oil (85 mg, 62%). 1H NMR (400 MHz, CDCl3): δ 7.82 (d, J = 8.1 Hz, 2 H), 7.29 (d, J = 8.1 
Hz, 2 H), 7.08 (d, J = 8.3 Hz, 2 H), 6.92 (d, J = 8.3 Hz, 2 H), 5.99 (d, J = 10.0 Hz, 1 H), 3.83 (s, 3 H), 
2.55 (s, 3 H), 2.25-2.17 (m, 1 H), 1.69-1.61 (ovrlp, 5 H), 1.25-1.17 (ovrlp, 5 H). 13C NMR (100 MHz, 
CDCl3): δ 197.7, 158.7, 148.1, 138.6, 138.2, 135.4, 132.1, 130.9, 128.3, 127.3, 113.8, 55.3, 38.6, 33.3, 
26.6, 26.0, 25.6. HRMS (ESI): Calcd for C23H27O2 [M+H]: 335.2003; Found: 335.2006.  
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(E)-1-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-3-methoxybenzene (3i). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
1-iodo-3-methoxybenzene (96 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (3i) as low-melting 
colorless solid (78 mg, 59%). 1H NMR (400 MHz, CDCl3): δ 7.16 (t, J = 8.2 Hz, 1 H), 7.10 (d, J = 8.3 
Hz, 2 H), 6.91 (d, J = 8.3 Hz, 2 H), 6.82 (d, J = 7.7 Hz, 1 H), 6.76-7.74 (ovrlp, 2 H), 5.88 (d, J = 9.8 Hz, 
1 H), 3.84 (s, 3 H) 3.75 (s, 3 H), 2.24-2.08 (m, 1 H), 1.75-1.60 (ovrlp, 5 H), 1.1-1.16 (ovrlp, 5 H). 13C 
NMR (100 MHz, CDCl3): δ 159.5, 158.6, 145.0, 139.1, 136.2, 132.9, 131.0, 129.0, 120.1, 113.6, 113.4, 
112.0, 55.34, 55.33, 38.4, 33.5, 26.2, 25.8. HRMS (ESI): Calcd for C22H27O2 [M+H]: 323.2011; Found: 
323.2005. 
 
 
 
 
 
 
 
 
(E)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-2-methylthiophene (3j). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
4-bromo-2-methylthiophene (73 mg), Ni(cod)2 (17 mg, 15 mol %), bipy (16 mg, 25 mol %), and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (3j) as viscous brown oil (70 mg, 55%). 1H NMR (400 MHz, 
CDCl3): δ 7.11 (d, J = 8.5 Hz, 2 H), 6.90 (d, J = 8.5 Hz, 2 H), 6.86 (s, 1 H), 6.42 (s, 1 H), 5.86 (d, J = 
9.9 Hz, 1 H), 3.84 (s, 3 H), 2.44 (s, 3 H), 2.11-1.96 (m, 1 H), 1.70-1.58 (ovrlp, 5 H), 1.19-1.14 (ovrlp, 5 
H). 13C NMR (100 MHz, CDCl3): δ 158.5, 144.8, 139.7, 134.7, 134.4, 132.7, 130.6, 124.0, 119.6, 113.6, 
55.4, 38.0, 33.5, 26.1, 25.8, 15.6. HRMS (ESI): Calcd for C20H25OS [M+H]: 313.1617; Found: 
313.1621. 
 
 
 
Methyl (E)-4-(2-Cyclohexyl-1-phenylvinyl)benzoate (3k). Following the general procedure A, the 
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alkenylzinc reagent was prepared using ethynylbenzene (72 mg) and iodocyclohexane (221 mg). 
Following the general procedure C, the title compound was prepared using methyl 4-iodobenzoate (107 
mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes as an eluent to afford the title compound (3k) as viscous pale-brown oil (107 mg, 65%). 
1H NMR (400 MHz, CDCl3): δ 7.91 (d, J = 8.0 Hz, 2 H), 7.39-7.32 (ovrlp, 3 H), 7.27 (d, J = 8.0 Hz, 2 
H), 7.14 (d, J = 7.2 Hz, 2 H), 6.0 (d, J = 10.0 Hz, 1 H), 3.88 (s, 3 H), 2.22-2.13 (m, 1 H), 1.68-1.60 
(ovrlp, 5 H), 1.25-1.15 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 167.1, 147.5, 139.9, 139.1, 138.1, 
129.8, 129.5, 128.4, 128.3, 127.2, 127.1, 52.1, 38.6, 33.3, 26.0, 25.6. HRMS (ESI): Calcd for C22H25O2 
[M+H]: 321.1855; Found: 321.1860. 
 
 
 
(E)-3-Cyclohexyl-1,2-diphenylprop-2-en-1-one (3l).38 Following the general procedure A, the 
alkenylzinc reagent was prepared using ethynylbenzene (72 mg) and iodocyclohexane (221 mg). 
Following the general procedure C, the title compound was prepared using benzoyl chloride (58 mg) and 
the alkenylzinc reagent prepared in the general procedure A by stirring at rt. The crude product was 
purified using hexanes as an eluent to afford the title compound (3l) as pale yellow oil (62 mg, 52%). 1H 
NMR (400 MHz, CDCl3): δ 7.77 (d, J = 7.6 Hz, 2 H), 7.50 (t, J = 7.3 Hz, 1 H), 7.42-7.36 (ovrlp, 4 H), 
7.31 (t, J = 7.5 Hz, 1 H), 7.25 (d, J = 7.6 Hz, 2 H), 6.26 (d, J = 10.4 Hz, 1 H), 2.39-2.30 (m, 1 H), 1.74-
1.57 (ovrlp, 5 H), 1.24-1.08 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 197.6, 150.2, 139.6, 138.6, 
136.5, 132.0, 129.8, 129.5, 128.3, 128.2, 127.5, 38.4, 32.5, 25.8, 25.3.  
 
 
 
(E)-2-Fluoro-5-(1-(4-methoxyphenyl)-3-methylpent-1-en-1-yl)pyridine (3m). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using 5-bromo-2-fluoropyridine 
(72 mg), Ni(cod)2 (17 mg, 15 mol %), bipy (16 mg, 25 mol %), and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes/EtOAc (50:1) as an eluent to 
afford the title compound (3m) as viscous pale-yellow oil (60 mg, 51%). 1H NMR (400 MHz, CDCl3): δ 
8.15 (s, 1 H), 7.65-7.61 (m, 1 H), 7.12 (d, J = 8.3 Hz, 2 H), 6.99 (d, J = 8.4 Hz, 2 H), 6.87-6.84 (m, 1 H), 
5.87 (d, J = 10.2 Hz, 1 H), 3.90 (s, 3 H), 2.40-2.29 (m, 1 H), 1.47-1.39 (m, 2 H), 1.08 (d, J = 6.6 Hz, 3 
H), 0.90 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 162.7 (d, JCF = 236.9 Hz), 158.9, 145.8 (d, 
JCF  = 14.5 Hz), 139.8 (d, JCF = 7.7 Hz), 137.8, 137.0 (d, JCF = 4.7 Hz), 136.0, 131.7, 130.8, 114.0, 108.7 
(d, JCF = 37.3 Hz), 55.4, 35.6, 30.4, 21.0, 12.1. HRMS (ESI): Calcd for C18H21FNO [M]: 286.1607; 
Found: 286.1608. 
O
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(E)-3-(1-(4-Methoxyphenyl)-3-methylpent-1-en-1-yl)quinolone (3n). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg, 0.70 mmol, 1 
equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using 3-bromoquionline (85 mg), 
Ni(cod)2 (17 mg, 15 mol %), bipy (16 mg, 25 mol %), and the alkenylzinc reagent prepared in the 
general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (3n) as viscous yellow oil (71 mg, 55%). 1H NMR (400 MHz, CDCl3): δ 8.94 (d, J = 1.6 Hz, 
1 H), 8.06 (d, J = 8.4 Hz, 1 H), 7.76 (s, 1 H), 7.69 (d, J = 8.1 Hz, 1 H), 7.63 (t, J = 8.0 Hz, 1 H), 7.47 (t, 
J = 7.7 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 2 H), 6.94 (d, J = 8.4 Hz, 2 H), 6.01 (d, J = 10.2 Hz, 1 H), 3.85 (s, 
3 H), 2.40-2.29 (m, 1 H), 1.41 (qu, J = 7.2 Hz, 2 H), 1.06 (d, J = 6.6 Hz, 3 H), 0.88 (t, J = 7.4 Hz, 3 H). 
13C NMR (100 MHz, CDCl3): δ 158.9, 150.1, 147.1, 138.4, 137.4, 135.9, 133.4, 131.9, 131.0, 129.2, 
129.0, 128.0, 127.9, 126.7, 114.0, 55.4, 35.8, 30.5, 21.0, 12.2. HRMS (ESI): Calcd for C22H24NO [M+H]: 
318.1858; Found: 318.1854. 
 
 
 
5-((1E,3Z)-3-(4-(tert-Butyl)phenyl)-5-methylhepta-1,3-dien-1-yl)benzo[d][1,3]dioxole (3o). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane 
(232 mg, 1.26 mmol, 1.8 equiv). Following the general procedure C, the title compound was prepared 
using (E)-5-(2-bromovinyl)benzo[d][1,3]dioxole (93 mg) and the alkenylzinc reagent prepared in the 
general procedure A. The crude product was purified using hexanes/EtOAc (100:1) as an eluent to 
afford the title compound (3o) as viscous brown oil (95 mg, 64%). 1H NMR (400 MHz, CDCl3): δ 7.38 
(d, J = 8.0 Hz, 2 H), 7.07 (d, J = 8.0 Hz, 2 H), 6.90 (s, 1 H), 6.81 (d, J = 15.9 Hz, 1 H), 6.71-6.66 (ovrlp, 
2 H), 5.92-5.88 (ovrlp, 3 H), 5.54 (d, J = 10.2 Hz, 1 H), 2.10-2.03 (m, 1 H), 1.36 (s, 9 H), 1.32-1.24 (m, 
2 H), 0.93 (d, J = 6.6 Hz, 3 H), 0.80 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 149.5, 148.1, 
146.8, 140.5, 140.2, 135.5, 132.6, 132.4, 129.3, 128.8, 125.1, 121.1, 108.3, 105.5, 101.0, 35.1, 34.7, 
31.6, 30.4, 21.2, 12.1. HRMS (ESI): Calcd for C25H31O2 [M+H]: 363.2324; Found: 363.2320. 
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1-(tert-Butyl)-4-((1E,3Z)-1-(4-chlorophenyl)-5-methylhepta-1,3-dien-3-yl)benzene (3p). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene 
(111 mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 
mmol, 1.8 equiv). Following the general procedure C, the title compound was prepared using (E)-1-(2-
bromovinyl)-4-chlorobenzene (89 mg) and the alkenylzinc reagent prepared in the general procedure A. 
The crude product was purified using hexanes as an eluent to afford the title compound (3p) as viscous 
brown oil (92 mg, 64%). 1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 7.8 Hz, 2 H), 7.24-7.19 (ovrlp, 4 
H), 7.07 (d, J = 7.8 Hz, 2 H), 6.93 (d, J = 16.0 Hz, 1 H), 5.93 (d, J = 16.0 Hz, 1 H), 5.60 (d, J = 10.2 Hz, 
1 H), 2.13-2.02 (m, 1 H), 1.37 (s, 9 H), 1.33-1.25 (m, 2 H), 0.93 (d, J = 6.6 Hz, 3 H), 0.80 (t, J = 7.4 Hz, 
3 H).13C NMR (100 MHz, CDCl3): δ 149.7, 141.8, 140.1, 136.5, 135.2, 134.6, 132.5, 129.2, 128.7, 
127.8, 127.5, 125.2, 35.2, 34.7, 31.6, 30.3, 21.1, 12.1. HRMS (ESI): Calcd for C24H29Cl [M]: 352.1913; 
Found: 352.1913. 
 
 
 
5-((1E,3Z)-4-Cyclohexyl-3-(4-methoxyphenyl)buta-1,3-dien-1-yl)-1,2,3-trimethoxybenzene (3q). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-
methoxybenzene (92 mg) and iodocyclohexane (221 mg). Following the general procedure C, the title 
compound was prepared using (E)-5-(2-bromovinyl)-1,2,3-trimethoxybenzene (112 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using 
hexanes/EtOAc (50:1) as an eluent to afford the title compound (3q) as yellow solid (122 mg, 73%). 1H 
NMR (400 MHz, CDCl3): δ 7.11 (d, J = 8.2 Hz, 2 H), 6.95 (d, J = 8.2 Hz, 2 H), 6.87 (d, J = 15.8 Hz, 1 
H), 6.53 (s, 2 H), 5.91 (d, J = 15.8 Hz, 1 H), 5.67 (d, J = 9.8 Hz, 1 H), 3.85 (s, 3 H), 3.84-3.79 (ovrlp, 9 
H), 2.06-1.99 (m, 1 H), 1.71-1.52 (ovrlp, 5 H), 1.20-1.11 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 
158.5, 153.3, 140.8, 138.9, 137.4, 133.61, 133.60, 130.61, 130.57, 129.2, 113.7, 103.2, 60.9, 56.0, 55.2, 
38.0, 33.2, 26.0, 25.6. HRMS (ESI): Calcd for C26H33O4 [M]: 409.2371; Found: 409.2373.  
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1-((1E,3Z)-4-Cyclohexyl-3-(4-methoxyphenyl)buta-1,3-dien-1-yl)-4-fluorobenzene (3r). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 
mg) and iodocyclohexane (221 mg). Following the general procedure C, the title compound was 
prepared using (E)-1-(2-bromovinyl)-4-fluorobenzene (82 mg) and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (3r) as white solid (94 mg, 68%). 1H NMR (400 MHz, CDCl3): δ 7.25 (dd, 3JHH = 7.0 Hz, 
3JCF = 7.0 Hz, 2 H), 7.08 (d, J = 8.4 Hz, 2 H), 6.96-6.92 (ovrlp, 4 H), 6.85 (d, J = 16.0 Hz, 1 H), 5.94 (d, 
J = 16.0 Hz, 1 H), 5.64 (d, J = 9.9 Hz, 1 H), 3.86 (s, 3 H), 2.04-1.92 (m, 1 H), 1.81-1.55 (ovrlp, 5 H), 
1.20-1.05 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 161.9 (d, J = 244.6 Hz), 158.6, 141.1, 139.0, 
134.1 (d, J = 3.3 Hz), 134.0 (d, J = 2.1 Hz), 130.7, 130.6, 128.1, 127.7 (d, J = 5.8 Hz), 115.5 (d, J = 21.4 
Hz), 113.8, 55.4, 38.0, 33.3, 26.1, 25.7. HRMS (ESI): Calcd for C23H26FO [M+H]: 337.1960; Found: 
337.1962. 
 
 
 
 (E)-(4-(3-Methyl-1-(p-tolyl)pent-1-en-1-yl)phenyl)(phenyl)methanone (3s). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using 4-benzoylphenyl 
trifluoromethanesulfonate (135 mg), Ni(cod)2 (23 mg, 20 mol %), bipy (20 mg, 30 mol %), and the 
alkenylzinc reagent prepared in the general procedure A by stirring at rt. The crude product was purified 
using hexanes as an eluent to afford the title compound (3s) as viscous brown oil (126 mg, 75%). 1H 
NMR (400 MHz, CDCl3): δ 7.78 (d, J = 7.2 Hz, 2 H), 7.70 (d, J = 8.3 Hz, 2 H), 7.56 (t, J = 7.3 Hz, 1 H), 
7.45 (t, J = 7.4 Hz, 2 H), 7.32 (d, J = 8.3 Hz, 2 H), 7.20 (d, J = 7.8 Hz, 2 H), 7.07 (d, J = 7.9 Hz, 2 H), 
5.78 (d, J = 10.2 Hz, 1 H), 2.39 (s, 3 H), 2.31-2.20 (m, 1 H), 1.37 (qu, J = 7.4 Hz, 2 H), 1.02 (d, J = 6.6 
Hz, 3 H), 0.85 (t, J = 7.5 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 196.4, 147.2, 139.8, 138.5, 138.0, 
137.0, 136.8, 135.7, 132.3, 130.2, 130.1, 129.8, 129.2, 128.3, 126.9, 35.8, 30.5, 21.4, 21.0, 12.2. HRMS 
(ESI): Calcd for C26H27O [M]: 355.2062; Found: 355.2064.  
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(E)-4-Methyl-1-morpholino-2-(p-tolyl)hex-2-en-1-one (3t). Following the general procedure A, the 
alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure C, the title compound was prepared using morpholine-4-carbonyl chloride (70 mg), 
Ni(cod)2 (17 mg, 15 mol %), bipy (16 mg, 25 mol %), and the alkenylzinc reagent prepared in the 
general procedure A by stirring at rt. The crude product was purified using hexanes as an eluent to 
afford the title compound (3t) as viscous brown oil (75 mg, 68%). 1H NMR (400 MHz, CDCl3): δ 7.21-
7.15 (ovrlp, 4 H), 5.61 (d, J = 10.5 Hz, 1 H), 3.64 (br s, 2 H), 3.46 (br s, 2 H), 2.51-2.42 (m, 1 H), 2.35 
(s, 3 H), 1.36 (qu, J = 7.2 Hz, 2 H), 1.01 (d, J = 6.6 Hz, 3 H), 0.85 (t, J = 7.4 Hz, 3 H). 13C NMR (100 
MHz, CDCl3): δ 170.7, 139.4, 137.5, 135.3, 133.0, 129.3, 128.4, 66.8, 47.6, 42.4, 34.2, 30.1, 21.3, 20.4, 
12.0. HRMS (ESI): Calcd for C18H26NO2 [M+H]: 288.1960; Found: 288.1958. 
 
 
 
(E)-2-(4-(tert-Butyl)phenyl)-4-methyl-1-phenylhex-2-en-1-one (3u). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 mmol, 1 
equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using benzoyl chloride (57 mg) and 
the alkenylzinc reagent prepared in the general procedure A by stirring at rt. The crude product was 
purified using hexanes as an eluent to afford the title compound (3u) as viscous brown oil (102 mg, 
77%). 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2 H), 7.50 (t, J = 7.2 Hz, 1 H), 7.43-7.37 
(ovrlp, 4 H), 7.19 (d, J = 8.0 Hz, 2 H), 6.16 (d, J = 10.5 Hz, 1 H), 2.53-2.42 (m, 1 H), 1.40-1.28 (ovrlp, 
11 H), 1.02 (d, J = 6.6 Hz, 3 H), 0.86 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 197.8, 150.5, 
150.2, 140.5, 138.7, 133.4, 132.0, 129.8, 129.1, 128.2, 125.2, 35.5, 34.7, 31.5, 29.9, 20.4, 12.1. HRMS 
(ESI): Calcd for C23H29O [M+H]: 321.2218; Found: 321.2220. 
 
 
 
 (E)-2-(4-(tert-Butyl)phenyl)-1-(4-methoxyphenyl)-4-methylhex-2-en-1-one (3v). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 
mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 
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1.8 equiv). Following the general procedure C, the title compound was prepared using 4-
methoxybenzoyl chloride (70 mg) and the alkenylzinc reagent prepared in the general procedure A by 
stirring at rt. The crude product was purified using hexanes as an eluent to afford the title compound 
(3v) as viscous brown oil (80 mg, 56%). 1H NMR (400 MHz, CDCl3): δ 7.84 (d, J = 8.6 Hz, 2 H), 7.37 
(d, J = 8.0 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 2 H), 6.90 (d, J = 8.5 Hz, 2 H), 6.05 (d, J = 10.5 Hz, 1 H), 3.84 
(s, 3 H), 2.54-2.43 (m, 1 H), 1.40-1.26 (ovrlp, 11 H), 1.03 (d, J = 6.6 Hz, 3 H), 0.88 (t, J = 7.4 Hz, 3 H). 
13C NMR (100 MHz, CDCl3): δ 196.5, 163.0, 150.1, 147.7, 140.3, 133.7, 132.3, 131.0, 129.0, 125.2, 
113.5, 55.5, 35.2, 34.6, 31.5, 30.0, 20.5, 12.1. GCMS: [M]+ = 350 was detected which corresponds to 
C24H30O2. 
 
 
 
(E)-2-(4-(tert-Butyl)phenyl)-1-(4-chlorophenyl)-4-methylhex-2-en-1-one (3w). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using 4-chlorobenzoyl chloride (72 
mg) and the alkenylzinc reagent prepared in the general procedure A by stirring at rt. The crude product 
was purified using hexanes as an eluent to afford the title compound (3w) as viscous brown oil (77 mg, 
53%). 1H NMR (400 MHz, CDCl3): δ 7.72 (d, J = 8.4 Hz, 2 H), 7.40-7.37 (ovrlp, 4 H), 7.16 (d, J = 8.2 
Hz, 2 H), 6.15 (d, J = 10.5 Hz, 1 H), 2.53-2.42 (m, 1 H), 1.40-1.31 (ovrlp, 11 H), 1.02 (d, J = 6.6 Hz, 3 
H), 0.86 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 196.4, 150.6, 150.4, 140.3, 138.3, 137.0, 
133.1, 131.2, 129.1, 128.6, 125.4, 35.5, 34.7, 31.5, 29.9, 20.4, 12.1. HRMS (ESI): Calcd for C23H28ClO 
[M+H]: 355.1829; Found: 355.1823. 
 
 
 
(Z)-1-(3,3-Dimethyl-1-phenylbut-1-en-1-yl)-4-methylbenzene (S3a).35 Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 
mmol, 1 equiv), Zn (137 equiv, 2.1 mmol, 3 equiv), TMSI (28 mg, 0.14 mmol, 20 mol %) and 2-iodo-2-
methylpropoane (386 mg, 2.1 mmol, 3 equiv). Following the general procedure C, the title compound 
was prepared using bromobenzene (65 mg, 0.70 mmol, 1 equiv) and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (S3a) as viscous pale yellow oil (44 mg, 42%). 1H NMR (400 MHz, CDCl3): δ 7.23-7.17 
(ovrlp, 5 H), 7.13 (d, J = 7.8 Hz, 2 H), 7.06 (d, J = 7.8 Hz, 2 H), 6.06 (s, 1 H), 2.37 (s, 3 H), 0.96 (s, 12 
H). 13C NMR (100 MHz, CDCl3): δ 144.4, 140.1, 139.1, 137.8, 136.3, 130.2, 128.5, 128.0, 126.9, 126.5, 
34.0, 31.4, 21.3.  
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4-((1E,3Z)-5-methyl-3-(p-tolyl)hepta-1,3-dien-1-yl)phenyl acetate (S3b). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure C, the title compound was prepared using (E)-4-(2-bromovinyl)phenyl 
acetate (99 mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was 
purified using hexanes as an eluent to afford the title compound (S3d) as brown solid (68 mg, 50%). 1H 
NMR (400 MHz, CDCl3): δ 7.29 (d, J = 8.4 Hz, 2 H), 7.20 (d, J = 7.6 Hz, 2 H), 7.04 (d, J = 7.7 Hz, 2 
H), 6.98 (d, J = 8.4 Hz, 2 H), 6.92 (d, J = 15.9 Hz, 1 H), 5.94 (d, J = 16.0 Hz, 1 H), 5.58 (d, J = 10.2 Hz, 
1 H), 2.39 (s, 3 H), 2.25 (s, 3 H), 2.11-2.00 (m, 1 H), 1.34-1.20 (m, 2 H), 0.93 (d, J = 6.6 Hz, 3 H), 0.79 
(t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 169.5, 149.6, 141.3, 140.2, 136.4, 135.8, 135.5, 
134.2, 129.5, 129.0, 128.2, 127.1, 121.6, 35.3, 30.3, 21.4, 21.2, 21.0, 12.1.  
 
 
 
Methyl (2E,4Z)-5-Cyclohexyl-4-(4-methoxyphenyl)penta-2,4-dienoate (S3c). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg) and 
iodocyclohexane (221 mg). Following the general procedure C, the title compound was prepared using 
methyl (Z)-3-iodoacrylate (87 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (S3e) as pale yellow 
solid (66 mg, 54%). 1H NMR (400 MHz, CDCl3): δ 7.47 (d, J = 15.5 Hz, 1 H), 7.00 (d, J = 8.4 Hz, 2 H), 
6.91 (d, J = 8.4 Hz, 2 H), 5.91 (d, J = 10.1 Hz, 1 H), 5.38 (d, J = 15.5 Hz, 1 H), 3.83 (s, 3 H), 3.69 (s, 3 
H), 2.10-1.96 (m, 1 H), 1.70-1.53 (ovrlp, 5 H), 1.21-1.05 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 
168.0, 158.9, 149.9, 148.6, 137.8, 130.3, 129.0, 118.3, 113.9, 55.3, 51.4, 38.4, 32.6, 25.9, 25.4.  
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1-((Z)-3,6-Dimethyldodec-4-en-5-yl)-4-methylbenzene (4a). Following the general procedure A, the 
alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure D, the title compound was prepared using 2-iodooctane (98 mg) and the alkenylzinc 
reagent prepared in the general procedure A. The crude product was purified using hexanes as an eluent 
to afford the title compound (4a) as viscous colorless oil (65 mg, 55%; Z:E > 20:1). 1H NMR (400 
MHz, CDCl3): δ 7.10 (d, J = 7.6 Hz, 2 H), 6.92 (d, J = 7.9 Hz, 2 H), 5.09 (d, J = 10.0 Hz, 1 H), 2.34-
2.26 (ovrlp, 4 H), 1.92-1.80 (m, 1 H), 1.36-1.14 (ovrlp, 12 H), 0.98-0.95 (m, 3 H), 0.91-0.84 (ovrlp, 6 
H), 0.76 (t, J = 7.3 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 144.6, 138.6 (138.4), 135.5, 132.9 (132.8), 
129.1, 128.4, 42.22 (42.18), 35.5 (35.4), 34.72 (34.68), 32.1, 30.51 (30.49), 29.64 (29.62), 27.7 (27.6), 
22.8, 21.6, 21.3, 20.5 (20.3), 14.3, 12.21 (12.19). HRMS (ESI): Calcd for C21H34 [M]: 286.2661; Found: 
286.2648. 
 
 
 
1-Methyl-4-((Z)-3,6,10-trimethylundeca-4,9-dien-5-yl)benzene (4b). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), 
Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure D, the title compound was prepared using 6-iodo-2-methylhept-2-ene (98 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (4b) as viscous colorless oil (64 mg, 55%; Z:E = 7.5:1). 1H 
NMR (400 MHz, CDCl3): δ 7.10 (d, J = 7.6 Hz, 2 H), 6.93 (d, J = 7.2 Hz, 2 H), 5.12-5.07 (ovrlp, 2 H), 
2.40-2.27 (ovrlp, 4 H), 2.05-1.95 (ovrlp, 2 H), 1.95-1.83 (m, 1 H), 1.68 (s, 3 H), 1.60 (s, 3 H), 1.45-1.36 
(m, 1 H), 1.26-1.13 (ovrlp, 3 H), 0.98 (d, J = 6.7 Hz, 3 H), 0.85 (d, J = 6.6 Hz, 3 H), 0.77 (t, J = 7.4 Hz, 
3 H). 13C NMR (100 MHz, CDCl3): δ 144.4, 138.40 (138.36), 135.6, 133.1 (133.0), 131.2, 129.2 
(129.1), 128.5, 125.11 (125.09), 41.93 (41.87), 35.5 (35.4), 34.72 (34.70), 30.49 (30.47), 26.29 (26.26), 
25.9, 21.65 (21.60), 21.3, 20.5 (20.3), 17.89 (17.86), 12.23 (12.20). HRMS (ESI): Calcd for C21H33 [M]: 
285.2582; Found: 285.2586. 
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1-((Z)-3,6-Dimethyl-1-phenyloct-4-en-4-yl)-4-methylbenzene (4c). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure E, the title compound was prepared using (3-iodobutyl)benzene (122 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (4c) as viscous colorless oil (84 mg, 58%; Z:E = 14:1). 1H 
NMR (400 MHz, CDCl3): δ 7.26 (d, J = 7.2 Hz, 2 H), 7.17-7.10 (ovrlp, 5 H), 6.96 (d, J = 7.7 Hz, 2 H), 
5.16 (d, J = 9.7 Hz, 1 H), 2.72-2.58 (m, 2 H), 2.39-2.29 (ovrlp, 4 H), 1.96-1.88 (m, 1 H), 1.74-1.65 (m, 1 
H), 1.55-1.47 (m, 1 H), 1.29-1.16 (m, 2 H), 1.04-1.02 (m, 3 H), 0.89-0.86 (m, 3 H), 0.82-0.76 (m, 3 H). 
13C NMR (100 MHz, CDCl3): δ 144.0, 143.1, 138.2 (138.1), 135.7, 133.6 (133.5), 129.1, 128.6 (128.5), 
128.4, 125.7, 42.0 (41.9), 37.2 (37.1), 34.8 (34.7), 34.1, 30.5, 21.62 (21.56), 21.3, 20.6 (20.4), 12.32 
(12.28). HRMS (ESI): Calcd for C23H31 [M+H]: 307.2426; Found: 307.2421. 
 
 
 
1-Methyl-4-((Z)-5-Methyl-2-phenylhept-3-en-3-yl)benzene (4d). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure E, the title compound was prepared using (1-bromoethyl)benzene (80 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (4d) as viscous colorless oil (66 mg, 50%; Z:E > 20:1). 1H 
NMR (400 MHz, CDCl3): δ 7.23-7.21 (m, 2 H), 7.17-7.12 (ovrlp, 3 H), 7.01-6.95 (m, 2 H), 6.73-6.68 
(m, 2 H), 5.28-5.20 (m, 1 H), 3.71-3.63 (m, 1 H), 2.29-2.27 (ovrlp, 3 H), 1.97-1.87 (m, 1 H), 1.38-1.35 
(ovrlp, 3 H), 1.30-1.15 (m, 2 H), 0.91-0.84 (m, 3 H), 0.80-0.73 (ovrlp, 3 H). 13C NMR (100 MHz, 
CDCl3): δ 145.2, 144.2 (144.1), 138.5 (138.3), 135.59 (135.58), 133.5, 129.01 (128.97), 128.38 
(128.34), 128.10 (128.09), 128.1 (128.0), 125.94 (125.93), 47.8 (47.7), 34.81 (34.78), 30.5, 21.5 (21.4), 
21.3, 20.35 (20.29), 12.24 (12.16). HRMS (ESI): Calcd for C21H27 [M]: 279.2113; Found: 279.2091. 
 
 
 
(Z)-1-methyl-4-(3-methyl-10-phenyldec-4-en-5-yl)benzene (4e). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure E, the title compound was prepared using (5-iodopentyl)benzene (129 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (4e) as colorless oil (90 mg, 60%; Z:E = 6.3:1). 1H NMR (400 
MHz, CDCl3): δ 7.28-7.23 (m, 2 H), 7.18-7.09 (ovrlp, 5 H), 6.98 (d, J = 7.6 Hz, 2 H), 5.11 (d, J = 10.0 
Me Me
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Hz, 1 H), 2.56 (t, J = 7.6 Hz, 2 H), 2.34 (s, 3 H), 2.26 (t, J = 7.1 Hz, 2 H), 2.07-1.96 (m, 1 H), 1.57 (qu, J 
= 6.3 Hz, 2 H), 1.36-1.28 (ovrlp, 4 H), 1.26-1.14 (m, 2 H), 0.87 (d, J = 6.6 Hz, 3 H), 0.76 (t, J = 7.3 Hz, 
3 H). 13C NMR (100 MHz, CDCl3): δ 143.0, 139.8, 139.1, 135.7, 133.6, 128.7, 128.5, 128.4, 128.3, 
125.7, 39.6, 36.1, 34.6, 31.4, 30.5, 28.9, 28.1, 21.4, 21.3, 12.1. HRMS (ESI): Calcd for C24H33 [M]: 
321.2582; Found: 321.2580. 
 
 
 
(Z)-1-(13-Chloro-3-methyltridec-4-en-5-yl)-4-methylbenzene (4f). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 mmol, 1 equiv), Zn 
(82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the 
general procedure E, the title compound was prepared using 1-chloro-8-iodooctane (129 mg) and the 
alkenylzinc reagent prepared in the general procedure A. The crude product was purified using hexanes 
as an eluent to afford the title compound (4f) as pale yellow oil (84 mg, 55%; Z:E = 6.5:1). 1H NMR 
(400 MHz, CDCl3): δ 7.12 (d, J = 7.5 Hz, 2 H), 6.99 (d, J = 7.8 Hz, 2 H), 5.12 (d, J = 10.0 Hz, 1 H), 
3.51 (t, J = 6.8 Hz, 2 H), 2.34 (s, 3 H), 2.26 (d, J = 6.1 Hz, 2 H), 2.08-1.97 (m, 1 H), 1.74 (qu, J = 7.4 
Hz, 2 H), 1.39 (qu, J = 7.6 Hz, 2 H), 1.31-1.15 (ovrlp, 10 H), 0.88 (d, J = 6.7 Hz, 3 H), 0.77 (t, J = 7.4 
Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 139.8, 139.2, 135.7, 133.5, 128.7, 128.4, 45.3, 39.7, 34.7, 
32.8, 30.5, 29.4, 29.1, 29.0, 28.2, 27.0, 21.5, 21.3, 12.1. HRMS (ESI): Calcd for C21H33Cl [M]: 
320.2271; Found: 320.2271.  
 
 
 
(Z)-1-(tert-Butyl)-4-(1-cyclohexyl-4-(4-methoxyphenyl)-3-methylbut-1-en-2-yl)benzene (4g). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg) and iodocyclohexane (221 mg). Following the general procedure D, the title 
compound was prepared using 1-(2-iodopropyl)-4-methoxybenzene (113 mg) and the alkenylzinc 
reagent prepared in the general procedure A. The crude product was purified using hexanes as an eluent 
to afford the title compound (4g) as viscous yellow oil (84 mg, 52%; Z:E = 8.2:1). 1H NMR (400 MHz, 
CDCl3): δ 7.30 (d, J = 8.0 Hz, 2 H), 7.04 (d, J = 8.4 Hz, 2 H), 6.97 (d, J = 8.0 Hz, 2 H), 6.78 (d, J = 8.3 
Hz, 2 H), 5.19 (d, J = 9.8 Hz, 1 H), 3.77 (s, 3 H), 2.77-2.72 (m, 1 H), 2.62-2.53 (m, 1 H), 2.35-2.29 (m, 
1 H), 1.92-1.83 (m, 1 H), 1.64-1.49 (ovrlp, 5 H), 1.33 (s, 9 H), 1.13-1.02 (ovrlp, 5 H), 0.94 (d, J = 6.8 
Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 157.7, 148.9, 143.4, 138.6, 133.7, 132.6, 130.2, 128.5, 124.7, 
113.5, 55.4, 43.5, 41.5, 37.3, 34.5, 33.8 (33.7), 31.6, 26.2 (25.8), 19.6. HRMS (ESI): Calcd for C28H39O 
[M+H]: 391.2991; Found: 391.2995. 
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(Z)-2-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)-2,3-dihydro-1H-indene (4h). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 
mg) and iodocyclohexane (221 mg). Following the general procedure D, the title compound was 
prepared using 1-(2-iodopropyl)-4-methoxybenzene (113 mg) and the alkenylzinc reagent prepared in 
the general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (4h) as white crystallize solid (89 mg, 61%; Z:E > 20:1). 1H NMR (400 MHz, CDCl3): δ 
7.32 (d, J = 7.9 Hz, 2 H), 7.16-7.11 (m, 2 H), 7.10-7.06 (m, 2 H), 7.03 (d, J = 8.0 Hz, 2 H), 5.35 (d, J = 
9.6 Hz, 1 H), 3.39-3.30 (m, 1 H), 2.93-2.80 (m, 4 H), 1.97-1.88 (m, 1 H), 1.63-1.52 (ovrlp, 5 H), 1.33 (s, 
9 H), 1.14-1.05 (ovrlp, 5 H). 13C NMR (100 MHz, CDCl3): δ 140.9, 143.5, 141.2, 138.3, 132.8, 128.5, 
126.1, 124.9, 124.3, 48.8, 38.3, 37.4, 34.6, 33.7, 31.6, 26.2, 25.8. GCMS: [M]+ = 358 was detected 
which corresponds to C27H34.  
 
 
 
(Z)-1-(tert-Butyl)-4-(3-methylpentadeca-4,14-dien-5-yl)benzene (4i). Following the general procedure 
A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 mmol, 1 
equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure E, the title compound was prepared using 10-iododec-1-ene (125 mg) 
and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified using 
hexanes as an eluent to afford the title compound (4i) as colorless oil (93 mg, 56%; Z:E = 6.7:1). 1H 
NMR (400 MHz, CDCl3): δ 7.30 (d, J = 8.1 Hz, 2 H), 7.02 (d, J = 8.0 Hz, 2 H), 5.85-5.75 (m, 1 H), 5.12 
(d, J = 10.1 Hz, 1 H), 4.98 (d, J = 17.2 Hz, 1 H), 4.92 (d, J = 10.1 Hz, 1 H), 2.26 (t, J = 6.9 Hz, 2 H), 
2.09-2.00 (ovrlp, 3 H), 1.36-1.19 (ovrlp, 23 H), 0.88 (d, J = 6.5 Hz, 3 H), 0.78 (t, J = 7.4 Hz, 3 H). 13C 
NMR (100 MHz, CDCl3): δ 148.8, 139.9, 139.4, 139.1, 133.4, 128.1, 124.8, 114.2, 39.7, 34.6, 34.5, 
34.0, 31.6, 30.6, 29.6, 29.5, 29.3, 29.1, 28.3, 21.5, 12.1. HRMS (ESI): Calcd for C26H43 [M+H]: 
355.3365; Found: 355.3361.  
 
 
 
 
 
 
 
 
(Z)-6-(4-(tert-Butyl)phenyl)-8-methyldec-6-en-1-yl acetate (4j). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 mmol, 1 
t-Bu
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equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure E, the title compound was prepared using 5-iodopentyl acetate (120 
mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes as an eluent to afford the title compound (4j) as pale-brown oil (86 mg, 53%; Z:E = 
7.1:1). 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 8.0 Hz, 2 H), 7.02 (d, J = 8.0 Hz, 2 H), 5.13 (d, J = 
10.1 Hz, 1 H), 4.02 (t, J = 6.7 Hz, 2 H), 2.28 (t, J = 6.8 Hz, 2 H), 2.10-2.00 (ovrlp, 4 H), 1.59 (d, J = 6.4 
Hz, 2 H), 1.37-1.19 (ovrlp, 15 H), 0.88 (d, J = 6.6 Hz, 3 H), 0.78 (t, J = 7.4 Hz, 3 H). 13C NMR (100 
MHz, CDCl3): δ 171.4, 149.0, 139.5, 138.8, 133.7, 128.1, 124.9, 64.8, 39.5, 34.6, 34.5, 31.6, 30.5, 28.5, 
27.9, 25.5, 21.5, 21.2, 12.1. HRMS (ESI): Calcd for C23H37O2 [M]: 345.2794; Found: 345.2789. 
 
 
 
(Z)-(3-Methylpentadec-4-en-5-yl)benzene (4k). Following the general procedure A, the alkenylzinc 
reagent was prepared using ethynylbenzene (71 mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 
equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). Following the general procedure E, the title 
compound was prepared using 1-iodooctane (126 mg) and the alkenylzinc reagent prepared in the 
general procedure A. The crude product was purified using hexanes as an eluent to afford the title 
compound (4k) as colorless oil (70 mg, 50%; Z:E = 8.5:1). 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 
7.2 Hz, 2 H), 7.21 (d, J = 6.9 Hz, 1 H), 7.10 (d, J = 7.6 Hz, 2 H), 5.15 (d, J = 10.1 Hz, 1 H), 2.28 (t, J = 
6.8 Hz, 2 H), 2.06-1.95 (m, 1 H), 1.31-1.19 (ovrlp, 18 H), 0.89-0.86 (ovrlp, 6 H), 0.77 (d, J = 7.4 Hz, 3 
H). 13C NMR (100 MHz, CDCl3): δ 142.3, 140.1, 133.6, 128.6, 128.0, 126.2, 39.7, 34.7, 32.1, 30.5, 
29.81, 29.77, 29.6, 29.5, 29.3, 28.2, 22.9, 21.4, 14.3, 12.1. GCMS (ESI): [M]+ = 300 was detected 
which corresponds to C22H36. 
 
 
 
3-((Z)-2-(4-(tert-Butyl)phenyl)-4-methylhex-2-en-1-yl)hexahydrofuro[2,3-b]furan (4l). Following 
the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene 
(111 mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 
mmol, 1.8 equiv). Following the general procedure E, the title compound was prepared using 2-
(allyloxy)-3-iodotetrahydrofuran (119 mg) and the alkenylzinc reagent prepared in the general procedure 
A. The crude product was purified using hexanes/EtOAc (100:1) as an eluent to afford the title 
compound (4l) as viscous pale brown oil (80 mg, 50%; Z:E = 7.3:1). 1H NMR (400 MHz, CDCl3): δ 
7.32 (d, J = 8.0 Hz, 2 H), 7.03 (d, J = 8.0 Hz, 2 H), 5.64 (d, J = 4.9 Hz, 1 H), 5.20 (d, J = 10.2 Hz, 1 H), 
3.92-3.79 (ovrlp, 3 H), 3.42 (t, J = 9.2 Hz, 1 H), 2.74-2.63 (m, 1 H), 2.48-2.25 (ovrlp, 3 H), 2.13-2.04 
(m, 1 H), 1.96-1.88 (m, 1 H), 1.84-1.73 (m, 1 H), 1.33 (s, 9 H), 1.27-1.17 (m, 2 H), 0.89 (d, J = 6.5 Hz, 3 
H), 0.79 (t, J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 149.5, 138.0, 137.6, 135.0, 128.0, 125.1, 
t-Bu
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110.0, 72.53 (72.47), 69.3, 45.6 (45.5), 40.4, 38.0, 34.6, 34.54 (34.45), 31.5, 30.4, 25.3, 21.4 (21.3), 
12.1. HRMS (ESI): Calcd for C21H31O2 [M]: 343.2637; Found: 343.2684. 
 
 
 
3-((Z)-4-Methyl-2-(p-tolyl)hex-2-en-1-yl)hexahydro-4H-furo[2,3-b]pyran (4m). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 
0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 
equiv). Following the general procedure E, the title compound was prepared using 2-(allyloxy)-3-
iodotetrahydro-2H-pyran (126 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes/EtOAc (100:1) as an eluent to afford the title compound (4m) 
as viscous pale brown oil (75 mg, 45%; Z:E = 7.2:1). 1H NMR (400 MHz, CDCl3): δ 7.13 (d, J = 7.8 
Hz, 2 H), 6.99 (d, J = 7.8 Hz, 2 H), 5.19-5.13 (ovrlp, 2 H), 3.81 (t, J = 7.4 Hz, 1 H), 3.74 (td, J = 9.6 Hz, 
J = 2.0 Hz, 1 H), 3.68-3.58 (ovrlp, 2 H), 2.49-2.40 (m, 1 H), 2.35 (s, 3 H), 2.32-2.25 (m, 2 H), 2.09-1.98 
(m, 1 H), 1.89-1.80 (m, 1 H), 1.73-1.51 (ovrlp, 3 H), 1.50-1.38 (m, 1 H), 1.33-1.14 (m, 2 H), 0.89-0.85 
(m, 3 H), 0.80-0.74 (m, 3 H). 13C NMR (100 MHz, CDCl3): δ 138.2, 137.70 (137.68), 136.3, 134.95 
(134.93), 129.0, 128.3, 102.1, 70.0 (69.9), 61.18 (61.16), 38.87 (38.85), 37.8 (37.7), 36.9 (36.8), 34.7 
(34.6), 30.4, 23.4, 21.33, 21.29, 19.61 (19.57), 12.12 (12.07). HRMS (ESI): Calcd for C21H31O2 [M+H]: 
315.2324; Found: 315.2328.  
 
 
 
1-((Z)-2,5-Dimethyl-1-phenylhept-3-en-3-yl)-4-methoxybenzene (S4a). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methoxybenzene (92 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure D, the title compound was prepared using (2-iodopropyl)benzene (101 
mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes as an eluent to afford the title compound (S4a) as colorless oil (61 mg, 48%; Z:E > 20:1). 
1H NMR (400 MHz, CDCl3): δ 7.26-7.23 (m, 2 H), 7.17-1.12 (ovrlp, 3 H), 6.98-6.95 (m, 2 H), 6.85 (d, J 
= 8.4 Hz, 2 H), 5.13 (d, J = 10.0 Hz, 1 H), 3.81 (s, 3 H), 2.84-2.76 (m, 1 H), 2.69-2.60 (m, 1 H), 2.42-
2.36 (m, 1 H), 1.94-1.83 (m, 1 H), 1.26-1.15 (m, 2 H), 0.98-0.95 (ovrlp, 3 H), 0.86-0.80 (m, 3 H), 0.74-
0.66 (ovrlp, 3 H). 13C NMR (100 MHz, CDCl3): δ 158.1, 143.8, 141.6 (141.5), 133.81 (133.79), 133.4 
(133.3), 130.23 (130.31), 129.34 (129.31), 128.1, 125.7, 113.3, 55.3, 43.71 (43.70), 42.4 (42.2), 34.7 
(34.6), 30.43 (30.42), 21.4 (21.3), 19.7 (19.5), 12.1 (12.0).  
 
 
 
Me
O
O
MeO
FMe
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1-((Z)-2,5-dimethyl-3-(p-tolyl)hept-3-en-1-yl)-4-fluorobenzene (S4b). Following the general 
procedure A, the alkenylzinc reagent was prepared using 1-ethynyl-4-methylbenzene (81 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure E, the title compound was prepared using 1-fluoro-4-(2-
iodopropyl)benzene (108 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes as an eluent to afford the title compound (S4b) as colorless oil 
(57 mg, 44%; Z:E  = 16:1). 1H NMR (400 MHz, CDCl3): δ 7.12 (d, J = 7.7 Hz, 2 H), 7.09-7.05 (m, 2 
H), 6.95-6.91 (ovrlp, 4 H), 5.11 (d, J = 10.0 Hz, 1 H), 2.79-2.72 (m, 1 H), 2.65-2.59 (m, 1 H), 2.40-2.30 
(ovrlp, 4 H), 1.93-1.83 (m, 1 H), 1.23-1.05 (m, 2 H), 0.98-0.95 (ovrlp, 3 H), 0.85-0.79 (m, 3 H), 0.74-
0.66 (ovrlp, 3 H). 13C NMR (100 MHz, CDCl3): δ 161.4 (JCF = 241.6 Hz), 143.9, 138.43 (138.37), 
137.12 (137.06) (JCF = 3.3 Hz), 135.8, 133.34 (133.31), 130.60 (130.56) (JCF = 7.7 Hz), 129.1 (129.0), 
128.6, 114.84 (113.83) (JCF = 20.9 Hz), 43.71 (43.68), 41.5 (41.3), 34.7 (34.6), 30.42 (30.40), 21.45 
(21.33), 21.31, 19.7 (19.5), 12.1 (12.0).   
 
 
 
(Z)-4-(3-(4-(tert-butyl)phenyl)-4-cyclohexyl-2-methylbut-3-en-1-yl)-1,2-dimethoxybenzene (S4c). 
Following the general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-
ethynylbenzene (111 mg) and iodocyclohexane (221 mg). Following the general procedure D, the title 
compound was prepared using 4-(2-iodopropyl)-1,2-dimethoxybenzene (126 mg) and the alkenylzinc 
reagent prepared in the general procedure A. The crude product was purified using hexanes/EtOAc 
(200:1) as an eluent to afford the title compound (S4c) as viscous yellow oil (64 mg, 37%; Z:E = 6.6:1). 
1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 7.7 Hz, 2 H), 6.97 (d, J = 7.8 Hz, 2 H), 6.75 (d, J = 7.8 Hz, 
1 H), 6.70-6.63 (ovrlp, 2 H), 5.22 (d, J = 9.7 Hz, 1 H), 3.84 (ovrlp, 6 H), 2.80-2.70 (m, 1 H), 2.65-2.55 
(m, 1 H), 2.37-2.31 (m, 1 H), 1.92-1.82 (m, 1 H), 1.68-1.48 (ovrlp, 5 H), 1.34 (s, 9 H), 1.13-1.10 (ovrlp, 
5 H), 0.96 (d, J = 6.6 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 148.9, 128.6, 147.1, 143.5, 138.6, 
134.3, 132.7, 128.5, 124.7, 121.3, 112.6, 111.0, 56.0, 55.9, 43.5, 42.0, 37.3, 34.5, 33.8 (33.7), 31.6, 26.2, 
25.8, 19.8.  
 
 
 
1-(tert-Butyl)-4-((Z)-1-methoxy-3,6-dimethyloct-4-en-4-yl)benzene (S4d). Following the general 
OMet-Bu
OMe
t-Bu
OMe
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procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 
mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure D, the title compound was prepared using 3-iodo-1-methoxybutane (88 
mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes as an eluent to afford the title compound (S4d) as viscous yellow oil (47 mg, 38%; Z:E > 
40:1). 1H NMR (400 MHz, CDCl3): δ 7.29 (d, J = 8.0 Hz, 2 H), 6.97 (d, J = 8.1 Hz, 2 H), 5.18-5.14 (m, 
1 H), 3.34-3.26 (ovrlp, 4 H), 3.16 (d, J = 8.2 Hz, 1 H), 2.43-2.36 (m, 1 H), 1.99-1.88 (m, 1 H), 1.48-1.41 
(m, 1 H), 1.32 (s, 9 H), 1.27-1.14 (ovrlp, 3 H), 0.98-0.94 (ovrlp, 3 H), 0.89-0.86 (m, 3 H), 0.81-0.76 (m, 
3 H). 13C NMR (100 MHz, CDCl3): δ 148.9, 139.6 (139.5), 137.6, 136.0 (135.9), 128.8 (128.7), 124.6, 
75.7 (75.6), 58.60 (58.56), 50.1, 34.8 (34.7), 34.5, 31.6, 30.5 (30.4), 22.9 (22.8), 21.7 (21.5), 12.22 
(12.18), 11.98 (11.97).  
 
 
 
(Z)-8-(4-(tert-Butyl)phenyl)-10-methyldodec-8-enenitrile (S4e). Following the general procedure A, 
the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 mg, 0.70 mmol, 1 
equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 1.8 equiv). 
Following the general procedure E, the title compound was prepared using 7-iodoheptanenitrile (111 
mg) and the alkenylzinc reagent prepared in the general procedure A. The crude product was purified 
using hexanes/EtOAc (50:1) as an eluent to afford the title compound (S4e) as viscous yellow oil (41 
mg, 26%; Z:E = 7.8:1). 1H NMR (400 MHz, CDCl3): δ 7.31 (d, J = 8.0 Hz, 2 H), 7.02 (d, J = 8.0 Hz, 2 
H), 5.13 (d, J = 10.1 Hz, 1 H), 2.29 (ovrlp, 4 H), 2.12-2.01 (m, 1 H), 1.61 (qu, J = 7.6 Hz, 2 H), 1.41 
(qu, J = 7.3 Hz, 2 H), 1.35-1.28 (ovrlp, 13 H), 1.26-1.40 (m, 2 H), 0.88 (d, J = 6.6 Hz, 3 H), 0.78 (t, J = 
7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 149.0, 139.4, 138.8, 133.7, 128.0, 124.9, 119.9, 39.9, 
34.6, 34.5, 31.5, 30.5, 28.6, 28.3, 27.9, 25.5, 21.5, 17.2, 12.1.   
 
 
 
(Z)-7-(4-(tert-Butyl)phenyl)-9-methylundec-7-en-1-yl thiophene-2-carboxylate (S4f). Following the 
general procedure A, the alkenylzinc reagent was prepared using 1-(tert-butyl)-4-ethynylbenzene (111 
mg, 0.70 mmol, 1 equiv), Zn (82 equiv, 1.26 mmol, 1.8 equiv), and 2-iodobutane (232 mg, 1.26 mmol, 
1.8 equiv). Following the general procedure E, the title compound was prepared using 6-iodohexyl 
thiophene-2-carboxylate (145 mg) and the alkenylzinc reagent prepared in the general procedure A. The 
crude product was purified using hexanes/EtOAc (100:1) as an eluent to afford the title compound (S4f) 
as viscous yellow oil (67 mg, 33%; Z:E = 7.1:1). 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 3.6 Hz, 1 
H), 7.53 (d, J = 4.9 Hz, 1 H), 7.30 (d, J = 8.1 Hz, 2 H), 7.08 (t, J = 4.4 Hz, 1 H), 7.02 (d, J = 8.0 Hz, 2 
H), 5.13 (d, J = 10.1 Hz, 1 H), 4.26 (d, J = 6.6 Hz, 2 H), 2.28 (t, J = 7.3 Hz, 2 H), 2.11-2.00 (m, 1 H), 
t-Bu
CN
t-Bu
O
O
S
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1.70 (qu, J = 7.1 Hz, 2 H), 1.42-1.28 (ovrlp, 15 H), 1.28-1.15 (m, 2 H), 0.88 (d, J = 6.5 Hz, 3 H), 0.78 (t, 
J = 7.4 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 162.5, 148.9, 139.6, 138.9, 134.3, 133.6, 133.3, 132.3, 
128.1, 127.8, 124.8, 65.4, 39.5, 34.55, 34.51, 31.6, 31.5, 30.5, 28.8, 28.1, 25.9, 21.5, 12.1.  
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Lists of NMR Spectra 
 
(E)-N,N-Dimethyl-4-(5-methyl-1-(4-(methylthio)phenyl)hept-3-en-1-yn-3-yl)aniline (2a) 
 
Me2N
SMe
Me2N
SMe
	   S58 
(E)-4-(3-(4-Bromophenyl)-5-methylhept-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2b) 
 
Br
SMe
Br
SMe
	   S59 
(E)-(4-(3-(4-Chlorophenyl)-4-cyclohexylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2c) 
 
Cl
SMe
Cl
SMe
	   S60 
(E)-1-(1-Cyclohexyl-4-phenylbut-1-en-3-yn-2-yl)-4-methoxybenzene (2d) 
 
MeO
MeO
	   S61 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-fluorobenzene (2e) 
 
MeO
F
MeO
F
	   S62 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-(trifluoromethyl)benzene 
(2f) 
 
MeO
CF3
MeO
CF3
	   S63 
(E)-1-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-4-nitrobenzene (2g) 
 
MeO
NO2
MeO
NO2
	   S64 
(E)-1-(5-Ethyl-1-(4-methoxyphenyl)undec-3-en-1-yn-3-yl)-4-methylbenzene (2h) 
 
Me
OMe
Me
OMe
	   S65 
(E)-4-(5-Ethyl-3-(p-tolyl)undec-3-en-1-yn-1-yl)benzonitrile (2i) 
 
Me
CN
Me
CN
	   S66 
(E)-1-(4-(5-Butyl-3-(p-tolyl)non-3-en-1-yn-1-yl)phenyl)ethan-1-one (2j) 
 
Me
O
Me
Me
O
Me
	   S67 
Methyl (E)-4-(5-Butyl-3-(p-tolyl)non-3-en-1-yn-1-yl)benzoate (2k)  
 
Me
O
OMe
Me
O
OMe
	   S68 
(E)-4-(2-(4-(tert-Butyl)phenyl)-4-(4-(methylthio)phenyl)but-1-en-3-yn-1-yl)tetrahydro-2H-
pyran (2l) 
 
t-Bu
SMe
O
t-Bu
SMe
O
	   S69 
(4-((E)-4-(Bicyclo[2.2.1]heptan-2-yl)-3-(p-tolyl)but-3-en-1-yn-1 yl)phenyl)(methyl)sulfane 
(2m) 
 
Me
SMe
Me
SMe
	   S70 
(E)-(4-(12-Chloro-3-(p-tolyl)dodec-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (2n) 
 
Me
Cl
SMe
Me
Cl
SMe
	   S71 
Methyl(4-(5-methyl-1-(3,4,5-trimethoxyphenyl)undec-3-en-1-yn-3-yl)phenyl)sulfane (2o) 
 
MeS
OMe
OMe
OMe
MeS
OMe
OMe
OMe
	   S72 
(E)-1-Bromo-4-(3-(4-(tert-butyl)phenyl)-5,5-dimethylhex-3-en-1-yn-1-yl)benzene (2p) 
 
t-Bu
Br
t-Bu
Br
	   S73 
(E)-1-(3-(4-(tert-Butyl)phenyl)-5,5-dimethylhex-3-en-1-yn-1-yl)-2-methylbenzene (2q)  
 
t-Bu
Me
t-Bu
Me
	   S74 
(4-((E)-4-(Adamantan-1-yl)-3-(4-methoxyphenyl)but-3-en-1-yn-1 yl)phenyl)(methyl)sulfane 
(2r) 
 
MeO
SMe
MeO
SMe
	   S75 
Methyl (E)-4-(4-(tert-Butyl)phenyl)-5-cyclohexylpent-4-en-2-ynoate (2s) 
 
t-Bu O
OMe
t-Bu O
OMe
	   S76 
(E)-4-(4-(tert-Butyl)phenyl)-5-cyclohexyl-1-morpholinopent-4-en-2-yn-1-one (2t) 
 
t-Bu O
N
O
t-Bu O
N
O
	   S77 
(E)-(4-((6-(4-(tert-Butyl)phenyl)-7-cyclohexylhept-6-en-4-yn-1-yl)oxy)phenyl)(phenyl)-
methanone (2u)  
 
t-Bu O
O
t-Bu O
O
	   S78 
(E)-2-(4-Cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)naphthalene (2v) 
 
	   S79 
(E)-1-Chloro-4-(4-cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)benzene (2w) 
 
Cl
Cl
	   S80 
(E)-(4-Cyclohexyl-3-phenylbut-3-en-1-yn-1-yl)triethylsilane (2x) 
 
SiEt3
SiEt3
	   S81 
(E)-3-(4-Cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)-9-ethyl-9H-carbazole (2y) 
 
MeO
N
Et
MeO
N
Et
	   S82 
(E)-5-Cyclohexyl-4-(4-methoxyphenyl)-1-phenylpent-4-en-2-yn-1-one (2z) 
 
MeO O
MeO O
	   S83 
(E)-2-((6-Cyclohexyl-5-(4-methoxyphenyl)hex-5-en-3-yn-1-yl)oxy)tetrahydro-2H-pyran 
(2aa) 
 
MeO
O O
MeO
O O
	   S84 
(E)-1-(tert-Butyl)-4-(4-cyclohexyl-3-(4-methoxyphenyl)but-3-en-1-yn-1-yl)benzene (S2a) 
 
MeO
t-Bu
MeO
t-Bu
	   S85 
(E)-(4-(3-(4-(tert-Butyl)phenyl)-4-cycloheptylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane 
(S2b) 
 
t-Bu
SMe
t-Bu
SMe
	   S86 
(E)-(4-(3-(4-(tert-Butyl)phenyl)-4-cyclooctylbut-3-en-1-yn-1-yl)phenyl)(methyl)sulfane (S2c) 
 
t-Bu
SMe
t-Bu
SMe
	   S87 
(E)-Methyl(4-(5-methyl-7-phenyl-3-(p-tolyl)hept-3-en-1-yn-1-yl)phenyl)sulfane (S2d) 
 
Me
SMe
Me
SMe
	   S88 
(E)-2-(5-Cyclohexyl-4-(4-methoxyphenyl)pent-4-en-2-yn-1-yl)isoindoline-1,3-dione (S2e) 
 
MeO
N
O
O
MeO
N
O
O
	   S89 
(E)-1-Chloro-4-((8-cyclohexyl-7-(4-methoxyphenyl)oct-7-en-5-yn-1-yl)oxy)benzene (S2f) 
 
MeO O
Cl
MeO O
Cl
	   S90 
(E)-7-Cyclohexyl-6-(4-methoxyphenyl)hept-6-en-4-yn-1-yl 4-chlorobenzoate (S2g) 
 
MeO O
O
Cl
MeO O
O
Cl
	   S91 
(E)-6-Methyl-4-(4-(methylthio)phenyl)dodec-4-en-2-yn-1-yl benzoate (S2h) 
 
MeS
O
O
MeS
O
O
	   S92 
Ethyl (E)-3-(2-Cyclohexyl-1-(p-tolyl)vinyl)benzoate (3a)  
 
Me
O
OEt
Me
O
OEt
	   S93 
4,4'-(2-Cyclohexylethene-1,1-diyl)bis(methylbenzene) (3b) 
 
Me Me
Me Me
	   S94 
Ethyl (E)-4-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)benzoate (3c) 
 
t-Bu
O
OEt
t-Bu
O
OEt
	   S95 
Ethyl (E)-5-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)thiophene-2-carboxylate (3d) 
 
t-Bu S
CO2Et
t-Bu S
CO2Et
	   S96 
(E)-1-(3-Methyl-1-(p-tolyl)pent-1-en-1-yl)-3-(trifluoromethyl)benzene (3e)  
 
Me
CF3
Me
CF3
	   S97 
(Z)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-N,N-diethylbenzamide (3f) 
 
MeO
O
NEt2
MeO
O
NEt2
	   S98 
(E)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-2-methylbenzonitrile (3g) 
 
MeO CN
Me
MeO CN
Me
	   S99 
(Z)-1-(4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)phenyl)ethan-1-one (3h) 
 
MeO
O
Me
MeO
O
Me
	   S100 
(E)-1-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-3-methoxybenzene (3i) 
 
MeO
OMe
MeO
OMe
	   S101 
(E)-4-(2-Cyclohexyl-1-(4-methoxyphenyl)vinyl)-2-methylthiophene (3j) 
 
MeO S
Me
MeO S
Me
	   S102 
Methyl (E)-4-(2-Cyclohexyl-1-phenylvinyl)benzoate (3k)  
 
O
OMe
O
OMe
	   S103 
(E)-3-Cyclohexyl-1,2-diphenylprop-2-en-1-one (3l) 
 
O
O
	   S104 
(E)-2-Fluoro-5-(1-(4-methoxyphenyl)-3-methylpent-1-en-1-yl)pyridine (3m) 
 
MeO N F
MeO N F
	   S105 
(E)-3-(1-(4-Methoxyphenyl)-3-methylpent-1-en-1-yl)quinoline (3n)  
 
MeO N
MeO N
	   S106 
5-((1E,3Z)-3-(4-(tert-Butyl)phenyl)-5-methylhepta-1,3-dien-1-yl)benzo[d][1,3]dioxole (3o) 
 
t-Bu O
O
t-Bu O
O
	   S107 
1-(tert-Butyl)-4-((1E,3Z)-1-(4-chlorophenyl)-5-methylhepta-1,3-dien-3-yl)benzene (3p) 
 
t-Bu
Cl
t-Bu
Cl
	   S108 
5-((1E,3Z)-4-Cyclohexyl-3-(4-methoxyphenyl)buta-1,3-dien-1-yl)-1,2,3-trimethoxybenzene 
(3q) 
 
MeO
OMe
OMe
OMe
MeO
OMe
OMe
OMe
	   S109 
1-((1E,3Z)-4-Cyclohexyl-3-(4-methoxyphenyl)buta-1,3-dien-1-yl)-4-fluorobenzene (3r) 
 
MeO
F
MeO
F
	   S110 
(E)-(4-(3-Methyl-1-(p-tolyl)pent-1-en-1-yl)phenyl)(phenyl)methanone (3s) 
 
Me
O
Me
O
	   S111 
(E)-4-Methyl-1-morpholino-2-(p-tolyl)hex-2-en-1-one (3t) 
 
Me O
N
O
Me O
N
O
	   S112 
(E)-2-(4-(tert-Butyl)phenyl)-4-methyl-1-phenylhex-2-en-1-one (3u) 
 
t-Bu O
t-Bu O
	   S113 
(E)-2-(4-(tert-Butyl)phenyl)-1-(4-methoxyphenyl)-4-methylhex-2-en-1-one (3v) 
 
t-Bu O
OMe
t-Bu O
OMe
	   S114 
(E)-2-(4-(tert-Butyl)phenyl)-1-(4-chlorophenyl)-4-methylhex-2-en-1-one (3w) 
 
t-Bu O
Cl
t-Bu O
Cl
	   S115 
(Z)-1-(3,3-Dimethyl-1-phenylbut-1-en-1-yl)-4-methylbenzene (S3a) 
 
Me
Me
	   S116 
4-((1E,3Z)-5-methyl-3-(p-tolyl)hepta-1,3-dien-1-yl)phenyl acetate (S3b)  
 
Me
O
O
Me
Me
O
O
Me
	   S117 
Methyl (2E,4Z)-5-Cyclohexyl-4-(4-methoxyphenyl)penta-2,4-dienoate (S3c) 
 
MeO
O
OMe
MeO
O
OMe
	   S118 
1-((Z)-3,6-Dimethyldodec-4-en-5-yl)-4-methylbenzene (4a) 
 
Me
Me
	   S119 
1-Methyl-4-((Z)-3,6,10-trimethylundeca-4,9-dien-5-yl)benzene (4b) 
 
Me
Me
	   S120 
1-((Z)-3,6-Dimethyl-1-phenyloct-4-en-4-yl)-4-methylbenzene (4c) 
 
Me
Me
	   S121 
1-Methyl-4-((Z)-5-Methyl-2-phenylhept-3-en-3-yl)benzene (4d) 
 
Me Me
Me Me
	   S122 
(Z)-1-methyl-4-(3-methyl-10-phenyldec-4-en-5-yl)benzene (4e) 
 
Me
Me
	   S123 
(Z)-1-(13-Chloro-3-methyltridec-4-en-5-yl)-4-methylbenzene (4f) 
 
Me
Cl
Me
Cl
	   S124 
(Z)-1-(tert-Butyl)-4-(1-cyclohexyl-4-(4-methoxyphenyl)-3-methylbut-1-en-2-yl)benzene (4g)  
 
OMet-Bu
OMet-Bu
	   S125 
(Z)-2-(1-(4-(tert-Butyl)phenyl)-2-cyclohexylvinyl)-2,3-dihydro-1H-indene (4h) 
 
t-Bu
t-Bu
	   S126 
(Z)-1-(tert-Butyl)-4-(3-methylpentadeca-4,14-dien-5-yl)benzene (4i) 
 
t-Bu
t-Bu
	   S127 
(Z)-6-(4-(tert-Butyl)phenyl)-8-methyldec-6-en-1-yl acetate (4j) 
 
O
OMe
t-Bu
O
OMe
t-Bu
	   S128 
(Z)-(3-Methylpentadec-4-en-5-yl)benzene (4k) 
 
	   S129 
3-((Z)-2-(4-(tert-Butyl)phenyl)-4-methylhex-2-en-1-yl)hexahydrofuro[2,3-b]furan (4l) 
 
t-Bu
O
O
t-Bu
O
O
	   S130 
3-((Z)-4-Methyl-2-(p-tolyl)hex-2-en-1-yl)hexahydro-4H-furo[2,3-b]pyran (4m) 
 
Me
O
O
Me
O
O
	   S131 
1-((Z)-2,5-Dimethyl-1-phenylhept-3-en-3-yl)-4-methoxybenzene (S4a) 
 
MeO
MeO
	   S132 
1-((Z)-2,5-dimethyl-3-(p-tolyl)hept-3-en-1-yl)-4-fluorobenzene (S4b) 
 
FMe
FMe
	   S133 
(Z)-4-(3-(4-(tert-butyl)phenyl)-4-cyclohexyl-2-methylbut-3-en-1-yl)-1,2-dimethoxybenzene 
(S4c) 
 
OMet-Bu
OMe
OMet-Bu
OMe
	   S134 
1-(tert-Butyl)-4-((Z)-1-methoxy-3,6-dimethyloct-4-en-4-yl)benzene (S4d) 
 
t-Bu
OMe
t-Bu
OMe
	   S135 
(Z)-8-(4-(tert-Butyl)phenyl)-10-methyldodec-8-enenitrile (S4e) 
 
t-Bu
CN
t-Bu
CN
	   S136 
(Z)-7-(4-(tert-Butyl)phenyl)-9-methylundec-7-en-1-yl thiophene-2-carboxylate (S4f) 
 
t-Bu
O
O
S
t-Bu
O
O
S
